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Abstract: Chronic myeloid leukemia (CML) is characterized by the presence of the BCR-ABL1 fusion
gene, which encodes a constitutive active tyrosine kinase considered to be the pathogenic driver
capable of initiating and maintaining the disease. Despite the remarkable efficacy of tyrosine kinase
inhibitors (TKIs) targeting BCR-ABL1, some patients may not respond (primary resistance) or may
relapse after an initial response (secondary resistance). In a small proportion of cases, development
of resistance is accompanied or shortly followed by progression from chronic to blastic phase (BP),
characterized by a dismal prognosis. Evolution from CP into BP is a multifactorial and probably
multistep phenomenon. Increase in BCR-ABL1 transcript levels is thought to promote the onset of
secondary chromosomal or genetic defects, induce differentiation arrest, perturb RNA transcription,
editing and translation that together with epigenetic and metabolic changes may ultimately lead to
the expansion of highly proliferating, differentiation-arrested malignant cells. A multitude of studies
over the past two decades have investigated the mechanisms underlying the closely intertwined
phenomena of drug resistance and disease progression. Here, we provide an update on what is
currently known on the mechanisms underlying progression and present the latest acquisitions on
BCR-ABL1-independent resistance and leukemia stem cell persistence.
Keywords: chronic myeloid leukemia; blastic phase; BCR-ABL1; tyrosine kinase inhibitors; resistance;
persistence
1. Introduction
Chronic Myeloid Leukemia (CML) is a clonal myeloproliferative disorder arising from a
multipotent hematopoietic stem cell (HSC). CML is characterized by a unique cytogenetic abnormality
involving the long arms of chromosomes 9 and 22, the t(9;22)(q34;q11) translocation, resulting in a
derivative 22q- traditionally known as the Philadelphia chromosome [1]. The translocation juxtaposes
the c-ABL oncogene 1 (ABL1) gene on chromosome 9 with the breakpoint cluster region (BCR) gene on
chromosome 22, causing the formation of the BCR-ABL1 fusion gene which encodes an oncoprotein
with enhanced tyrosine kinase activity. It is believed that the acquisition of this fusion gene occurs
in a single HSC that gains a proliferative advantage and/or aberrant differentiation capacity with
consequent expansion of the myeloid compartment [2]. CML is characterized by a triphasic clinical
course. More than 90% of CML cases are diagnosed in an early phase known as chronic phase
(CP). Up to 50% of patients are asymptomatic at this stage and the disease is diagnosed by routine
blood tests. Common findings at the time of diagnosis are fatigue, weight loss, abdominal fullness,
bleeding, purpura, splenomegaly, leukocytosis, anemia, and thrombocytosis [1]. In this initial stage,
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mature granulocytes are still produced but there is an increased pool of myeloid progenitor cells
in the peripheral blood (PB). If not effectively treated, CML may progress to an accelerated phase
(AP), that is variable in duration and may be followed by a blastic phase (BP), which resembles
morphologically acute leukemia: myeloid and/or lymphoid differentiation stops and immature blasts
accumulate in the bone marrow (BM) spreading then to tissues and organs. Twenty to 25% of patients
may develop BP without going through the intermediate AP. There is currently no consensus between
the European Leukemia Net (ELN) and the World Health Organization (WHO) as to the percentage of
blasts concurring to the definition of BP. According to the former, BP is defined by ≥30% blasts in the
bone marrow or peripheral blood or extramedullary disease apart from spleen. The WHO instead
sets the percentage of blasts required for BP definition at 20% [3]. Before the advent of ABL1 tyrosine
kinase inhibitors (TKIs), blasts were usually of myeloid phenotype in approximately 70% of CML-BP
patients and of B-Lymphoid phenotype in approximately 30% of patients; rarely, mixed phenotypes
were found. In the TKI-era, the blastic transformation of CML with mixed phenotype is getting even
more rare. In the myeloid phenotype, blasts can be neutrophilic, eosinophilic, basophilic, monocytic,
megakaryocytic, or erythroid [4–6]. Rarely, cases of T-lymphoid and promyelocytic-BP have been
documented [7,8] and they are even more rare during TKI treatment [9,10]. Looking at gene expression
profiling during the evolution, the progression from CP to advanced phases has been described as a
two-step rather than a three-step process. Gene expression patterns resulted to be very similar between
accelerated and blast phases and crucial steps in progression show up at the transition of CP to AP
when a block of differentiation and apoptosis, alterations in cell adhesion, activation of alternative
signaling pathways, and a shift toward turning on expression of genes involved in the nucleosome are
observed [11].
CP CML patients can successfully be treated with ABL1 TKIs. The first one to be introduced was
imatinib mesylate, which showed a high rate of responses and an acceptable side effect profile when
evaluated as initial therapy for newly diagnosed CP CML in the pivotal IRIS study. However, some
patients may not respond to imatinib (primary resistance) and others relapse after an initial response
(secondary resistance). In a small proportion of cases, development of resistance is accompanied or
shortly followed by progression to BP. The problem of resistance has been the main trigger for the
development of second-generation TKIs (2G-TKIs)—first approved for imatinib-resistant patients
and later as frontline therapy. Today three 2G-TKIs (bosutinib, dasatinib, and nilotinib) are available
and significant clinical benefit as compared to imatinib has been demonstrated by randomized
clinical trials [12–14]. A third generation TKI (ponatinib) is also available for patients with a peculiar
TKI-resistant mutation in the BCR-ABL1 gene (the T315I, against whom imatinib and 2G-TKIs are
ineffective; discussed in detail below) or for whom no other TKI is indicated. However, TKIs have
only modestly improved survival of BP patients. Indeed, in a cohort study of 477 BP-CML patients,
Jain et al. observed an overall survival (OS) of 12 months [15]. Therefore, preventing rather than
counteracting disease progression is essential in an attempt to improve outcomes as well as healthcare
resource utilization [15]. For almost two decades, a multitude of research studies have investigated the
mechanisms underlying the closely intertwined phenomena of drug resistance and disease progression,
with the aim to identify dysregulated molecules, validate new druggable targets and optimize treatment
decision algorithms. This review provides a comprehensive overview of what is currently known and
discusses what would deserve further investigation in an attempt to optimize patient outcomes.
2. Overview of Known Mechanisms Underlying Progression to BP
The BCR-ABL1 oncogene arises in a primitive cell named leukemia stem cell (LSC), not yet
committed to either myeloid or lymphoid differentiation. The blastic clone may originate either
at the level of the multipotent LSC (CD34+CD38-Lin-) or at the level of a more committed
granulocyte-macrophage progenitor cell, where the activation of β-catenin [16,17] and of hairy
enhancer of split 1 (Hes1) [18] appear to be among the key events responsible for the re-acquisition of
self-renewal capacity and enhancement of leukemic potential.
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Since the BCR-ABL1 oncoprotein is found in the cytoplasm [19], it can interact with many cellular
substrates leading to abnormal pathways activation. By now, the oncoprotein is recognized to enhance
proliferation activating Ras-mitogen-activated protein kinase (MAPK), to increase the transcriptional
activity perturbing the JAK-STAT pathway, to decrease the apoptosis activating phosphatidylinositol
3-kinase (PI3K)/AKT pathway and to alter the expression of several genes/molecules implicated in
cell adhesion and motility like L-selectin, ICAM-1, and CCR7. BCR-ABL1 is necessary for malignant
transformation but not sufficient to sustain BP. As matter of fact, the expression levels of BCR-ABL1
(both at the mRNA and protein level) increase with disease progression [20,21], promoting the onset
of secondary molecular and chromosomal “hits” which ultimately lead to the expansion of highly
proliferating differentiation-arrested malignant cell clones. Once these ‘’hits” have been acquired,
inhibiting BCR-ABL1 alone often fails, as testified by the low efficacy of TKI treatment in the advanced
phases of the disease. However, although BCR-ABL1 is likely to be the primum movens responsible
for the acquisition of many of the additional hits that have been implicated in disease progression, the
fact that some patients suddenly progress while on TKI treatment suggests that disease progression
may also involve BCR-ABL1-independent mechanisms. Evolution from CP into BP is a multifactorial
and probably multistep phenomenon, and although hundreds of studies have been performed to
dissect progression mechanisms, some pieces of the puzzle are still missing. It is believed that disease
progression may be triggered by a series of distinct but functionally equivalent events in different
patients, whereby the increase in BCR-ABL1 transcript levels cooperate with BCR-ABL1-dependent
and –independent genomic instability to determine the accumulation of key events at the DNA, RNA
and protein level that converge to subvert cell cycle control, differentiation, apoptosis (Figure 1).
Figure 1. Overview of BCR-ABL1-dependent mechanisms. High BCR-ABL1 expression and activity in
chronic myeloid leukemia (CML) implicate alteration of the normal cellular and genetic characteristics
leading to transformation and progression to advanced phases.
3. BCR-ABL1 and Genomic Instability
The frequency of numerical and structural chromosomal changes results to be much higher in
BP-CML compared with CP-CML. Studies in pediatric and adult CML patients showed that copy
number alterations (CNAs) are rare or absent in CML-CP but increase upon disease progression, a sign
of the increasing genomic instability [22–27].
BCR-ABL1 is considered a direct cause of genomic instability since its expression and activity are
responsible for the generation of reactive oxygen species (ROS), disruption of DNA repair pathways
and inhibition of DNA damage-induced apoptosis that may result in aneuploidy, chromosomal
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alterations, DNA deletions and insertions, and point mutations (Figure 2). The involvement of ROS
in genomic instability and CML progression has been extensively reviewed [28]. Controlling the
levels of intracellular ROS is one of the mechanisms required to guarantee genomic integrity, because
ROS can damage both the nucleobases and the deoxyribose incorporated in DNA as well as the free
nucleotides, leading to oxidized bases and DNA double-strand breaks (DSBs). BCR-ABL1 kinase
activity has been found to elevate intracellular ROS levels [29], and this was markedly more evident
in BP CML cells, exhibiting higher BCR-ABL1 levels, than in CP CML cells [30]. If, on one hand,
ROS levels and exogenous factors such as radiations or genotoxic compounds may enhance oxidative
DNA damage, on the other hand the DNA repair machinery are deregulated by loss or gain of function
in BCR-ABL1-positive cells [31]. In human cells, DSBs are preferentially repaired by homologous
recombination (HR) or non-homologous end joining (NHEJ), but sometimes the highly unfaithful
single-strand annealing (SSA) mechanism may operate [32]. Novicki et al. have demonstrated an
enhanced activity of HR and NHEJ in the repair of ROS-mediated DSBs in BCR-ABL1 cells, where
these mechanisms resulted to be unfaithful, causing mutations and large deletions. As matter of
fact, it has later been demonstrated that BCR-ABL1 (non mutated and T315I mutant) may bind and
phosphorylate RAD51, as well as its paralog, RAD51B, promoting unfaithful homologous HR in a
dosage-dependent manner.
Figure 2. The role of BCR-ABL1 in the genomic instability. High levels of BCR-ABL1 are responsible
for the generation of reactive oxygen species (ROS) and stimulate unfaithful DNA repair mechanisms
(HRR= homologous recombination repair, NHEJ = nonhomologous end-joining, SSA = single-cell
annealing) thus leading to increased DNA damage.
Another key player in HR, BRCA1, has been found to be downregulated in cell lines and primary
samples from patients with CP and BP [33]. Reduced BRCA1 protein levels in CML has been ascribed
to BCR-ABL1-dependent inhibition of BRCA1 mRNA translation [34] and to BCR-ABL1-dependent
downregulation of the BRCA1-associated protein 1 (BAP1) deubiquitinase [35].
Since 2002 an increased error-prone repair by NHEJ had been remarked in myeloid leukemia cells.
The ‘’canonical” NHEJ pathway in human cells is triggered by the recognition and binding of DSBs
by Ku70 and Ku80, which recruit the DNA-dependent protein kinase catalytic subunit (DNA-PKcs)
to form the functional DNA-dependent protein kinase (DNA-PK). DNA-PK serves as a bridge to
mediate the ligation of DNA ends by the DNA ligase IV (LIG4) complex and activates the Artemis
nuclease which is required, together with DNA polymerases mu and lambda (Pol µ and Pol λ,),
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to create ligatable ends [36]. However, an alternative (“backup”) NHEJ, slow and error-prone, may be
carried out by a different subset of proteins—including poly (ADP-ribose) polymerase (PARP) and
DNA ligase IIIa (LIG3a). In CML, Artemis and LIG4 have been found to be downregulated, whereas
LIG3a and the Werner helicase (WRN) are upregulated and form a novel complex acting on DSBs in
BCR-ABL1-positive cells [37]. BCR-ABL1 has later been found to induce WRN mRNA and protein
expression by c-MYC-dependent activation of transcription and BCL-Xl-dependent inhibition of caspase
cleavage, respectively [38]. BCR-ABL1 can complex with and phosphorylate WRN, stimulating its
helicase and hexonuclease activites [38] increasing the infidelity of NHEJ and enhancing the activity of
the more unfaithful HR and SSA. SSA mediates the annealing of complementary single strands formed
after extensive resection at DSBs until repeated sequences are detected. BCR-ABL1 has been reported
to stimulate SSA by upregulating RAD52 and ERCC1, which may also result in an accumulation
of chromosomal aberrations such as translocations, partial deletions (e.g tumor suppressor genes)
and duplications.
The mismatch repair (MMR) system has the role to maintain genomic stability by detecting
misincorporated nucleotides, by acting an excision repair before point mutations emerge and by
inducing cell apoptosis in case of unrepairable DNA damage. Following the observation that a
certain degree of microsatellite instability can be observed at multiple loci in BP-CML differently to
CP-CML [39], Stoklosa et al. have demonstrated that the BCR-ABL1 kinase is responsible for reduced
MMR activity. The efficacy of MMR was reduced ∼2-fold in BCR-ABL1-positive cell lines and in
CD34+ CML cells as compared to normal counterparts. Impaired MMR activity in leukemia cells
was associated with accumulation of p53 but not of p73, and lack of activation of caspase 3 after
treatment with DNA damage-inducing agents. This resulted in a 15-fold increase in mutation rate in
BCR-ABL1-positive cells. The resulting ‘’mutator phenotype” may be the primary responsible for the
accumulation of point mutations in the BCR-ABL1 kinase domain (KD) sequence and in other key
genes, causing TKI-resistance, and promoting the disease progression. Defective base excision repair
(BER) may also contribute to the accumulation of point mutations. BER is primarily responsible for the
correction of DNA damage by oxidation, alkylation, and deamination processes. In the stem/progenitor
cell compartment, BCR-ABL1 has been found to inhibit in a kinase-dependent manner the activity
of uracil-N-glycosylase 2 (UNG2), one of the key enzymes that initiates BER by recognizing and
eliminating the damaged DNA bases [40].
4. Additional Chromosomal Abnormalities
In Philadelphia-positive clones, the classical t(9;22)(q34;q11) can be found in combination with
secondary chromosomal aberrations known as additional chromosomal abnormalities (ACAs) [41].
The presence of ACAs can be observed at diagnosis in ≈5% or less of CP CML patients as demonstrated
by several studies [42–44]. The European LeukemiaNet recommendations suggest that the presence of
ACAs at diagnosis should be considered a “warning” sign for patients in early CP, requiring a closer
monitoring of this subset of patients. The appearance of ACAs on treatment is well known as clonal
evolution (CE) and it has been associated with disease evolution since ACAs frequency is higher in
advanced phases, AP (≈30%) and BP (≈80%) [45–47]. However, ACAs constitute a heterogeneous
collection of karyotype abnormalities with different frequency and different prognostic significance.
Mitelman classified them into “major” and “minor” route chromosomal abnormalities according
to the frequency of the pathways of cytogenetic evolution followed by CML cells during disease
progression. The most common ACAs involved in karyotype evolution are trisomy 8 (the most
frequent), a second Ph chromosome, an isochromosome 17 (i(17q)) and trisomy 19. These aberrations
are called “major route changes” [48,49]. At least one of these four major karyotipic changes is found
in 71% of CML cases with cytogenetic abnormalities in addition to the Ph chromosome [49]. Some
among the infrequent cytogenetic changes are trisomies of chromosomes 17 and 21, monosomies of
chromosomes 7, 17 and 21, translocations t(3;12), t(4;6), t(2;16), and t(1;21). They are known as “minor
route changes” and at least one of them occurs in 15% of all Ph-positive CML patients with additional
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cytogenetic abnormalities [49]. The lack of the Y chromosome, observed in 5% of Ph+ patients [49], has
also been recognized as a minor route ACA. The prognostic significance of ACAs in CP CML patients
at diagnosis is still debated. Whereas some studies associated the presence of ACAs in general [50–52]
or major route abnormalities to worse progression-free survival and/or overall survival [53–55] others
failed to find any significantly association [8,56].
5. Gene Mutations and Submicroscopic Genetic Abnormalities
The most frequently mutated gene in CML is BCR-ABL1 itself. Point mutations within the ABL1
KD may indeed be selected during TKI therapy, leading to treatment failure. Mutations disrupt critical
contact residues between the TKIs and their target, or induce a shift to a conformation that TKIs
may be unable to bind (e.g, from the closed to the open conformation of the kinase, that imatinib
and nilotinib cannot recognize). The frequency of BCR-ABL1 KD mutations [57] is relatively low
(25% to 30%) in CP patients on first-line therapy but increases up to 70%–80% in BP patients [58,59].
BP patients, much more frequently than CP patients, may accumulate multiple BCR-ABL1 KD
mutations as a result of sequential therapy with TKIs. Multiple mutations arising in the same
molecule (compound mutations) can be observed in more than 30% of BP patients and are particularly
challenging [9,60–63]. In vitro studies [64] have shown that they are highly resistant to 2GTKIs and
in some cases even to ponatinib. Beyond BCR-ABL1 KD point mutations, other genetic lesions have
been described with different patterns in myeloblastic and lymphoblastic transformations. The most
common detectable gene alterations ‘’historically” reported in myeloid BP cases (20% to 30%) before
the advent of high throughput technologies, involved the tumor suppressor gene TP53, mapping at
17p13.1 [65]. These alterations usually consist in the loss of one TP53 allele (e.g., as a consequence
of structural alterations like i(17p)) and in point mutations in the coding sequence of the remaining
allele [66].The p53 tumor suppressor is the master regulator of the DNA damage checkpoint. Mice
injected with p53-deficient BCR-ABL1-expressing bone marrow cells developed a more aggressive
disease than those injected with the wild-type p53 counterpart [67]. Blastic transformation was also
observed in a transgenic model in which mice expressing BCR-ABL1 under the control of the Tec
promoter were crossed with p53-heterozygous (p53+/-) mice [68]. Functional p53 has been involved in
imatinib-induced apoptosis [69]. RB1 inactivating mutations or deletions are the second most frequent
genetic abnormality detected in myeloid BP (20% of cases) [70,71].The RB tumor suppressor protein
restricts cell cycle progression at the G1/S checkpoint until a cell is ready to divide. Point mutations
within the DNA-binding region of the RUNX1 gene were first described in association with trisomy 21
in some myeloid BP [72]. A later study in a large cohort of Chinese CML-AP and CML-BP patients
identified missense, nonsense, and frameshift RUNX1 mutations displaying a reduced transactivation
activity and/or a dominant-negative function over the wild-type RUNX1 in 12% of the cases [73].
The RUNX1 gene, located on chromosome 21q22, encodes the major subunit of the heterodimeric
core binding factor (CBF) complex, a transcription factor essential for myeloid differentiation. In
a mouse model, runx1 mutations were found to perturb myeloid differentiation and induce an AP
or BP–like phenotype [73]. Chromosomal translocations involving the RUNX1 gene have also been
reported in BP-CML. The t(3;21)(q26;q22) translocation can be observed in BP CML patients and
also in therapy-related AML and myelodysplasia (MDS) [74–78]. Consequently to this translocation,
RUNX1 resulted to be fused with EAP, EVI1 and MDS, or both MDS1 and EVI1. EVI1 (also known
as MECOM or PRDM3) plays an important role as regulator of self-renewal in hematopoietic stem
cells [79]. A study in a transgenic zebrafish model showed the capability of this fusion gene to inhibit
myeloid cell differentiation and to induce resistance to apoptosis [80].
In lymphoid BP, one of the most frequent abnormalities (detected in approximately 50% of cases),
known even before the advent of genome-wide technologies [57,81,82] is represented by monoallelic
or biallelic deletions of the CDKN2A/B locus, encoding the tumor suppressors and cell cycle regulators
INK4A, INK4B, and ARF. The CDKN2A and CDKN2B genes encode p16INK4A and p15INK4B, which
are inhibitors of cyclin-dependent kinases. In addition, transcription of an alternate reading frame
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of the CDKN2A locus produces p14ARF, which antagonizes the p53 ubiquitin ligase, MDM2. Thus,
the INK4-ARF locus regulates both RB and p53 function to prevent an inappropriate progenitor cell
self-renewal and to eliminate cells driven by oncogenic signaling [83].
The recent advent of high throughput technologies like DNA microarrays and next generation
sequencing (NGS) has contributed to further unravel the genetic/genomic complexity of BP cells.
Array-CGH and SNP-arrays [22–26,84,85]; have highlighted the presence of multiple recurrent
submicroscopic genomic lesions in myeloid and lymphoid BP. In the latter, as well as in acute
lymphoblastic leukemias, such methodologies have enabled the characterization of IKZF1 loss [86].
The IKZF1 gene on chromosome 7 encodes IKAROS, a transcription factor essential for lymphoid
development. Detected early in hematopoietic development, IKAROS expression plays a key role
in shutting down stem-cell programs and driving cells towards lymphoid development [87,88].
Monoallelic and bi-allelic deletions of the whole gene or focal in-frame deletions of exons 4 to 7, creating
a dominant negative isoform (Ik6) lacking the DNA-binding domain have been reported [86,89–91].
NGS has also contributed to pinpoint sequence and structural alterations associated with
TKI-resistance and disease progression. An IDH2 mutation was detected by whole transcriptome
sequencing in a CML case who had progressed to lymphoid BP while on nilotinib treatment and
subsequently reported in 3/75 myeloid BP and 1/31 lymphoid BP patients [92]. No IDH1 mutation
emerged in that study. Using a targeted NGS approach to screen for mutations 12 candidate genes in 39
BP cases, Grossman et al. reported mutations in RUNX1, IKZF1, ASXL1, WT1, TET2, CBL, IDH1, NRAS,
KRAS, and TP53 overall occurring in 76.9% of the patients. RUNX1, ASXL1 and IKZF1 had the highest
mutation rate [93]. Makishima et al. screened Janus kinase (JAK)-2, CBL, CBLB, TET2, ASXL1, IDH1,
and IDH2 coding sequences in 26 BP patients, identifying four TET2, two ASXL1, two IDH1/2, one CBL
and one CBLB mutations in myeloid BP [94]. A whole exome sequencing analysis of 10 matched
CP-BP samples has more recently uncovered that UBE2A mutations may recurrently (16.7% of cases in
the validation cohort) be acquired at the time of progression [95]. Functional studies have revealed
that mutations abrogate UBE2A activity, leading to an impairment of myeloid differentiation [95].
At present, the largest study taking advantage of an integrated approach of whole-exome sequencing,
copy-number variation (CNV) analysis and RNA sequencing in CML patients has been performed
by Branford et al. [96]. This study has revealed one or multiple mutations in all BP patients tested,
CNVs in 90% of cases and gene fusions other than BCR-ABL1 in 42% of cases [96]. Genes affected by
missense, nonsense, frameshift, or splice site mutations included BCR-ABL1, ASXL1, RUNX1, IKZF1,
BCOR, BCORL1, GATA2, PHF6, SETD1B, SETD2, U2AF1, IDH1/2, KMT2D, and XPO1. Among CNVs,
a novel recurrent 60-Kb deletion comprising exons 1 to 2 of the HBS1L gene and an intergenic sequence
between HBS1L and MYB was detected in 3 of 10 patients with lymphoid BP. Known and novel fusions
were also detected by RNA-seq. MLL (KMT2A) fusions (some of whom were cytogenetically cryptic)
were the most frequent. The other known fusions were CBFB-MYH11 and PAX5-ZCCHC7. Novel
fusions resulting from intra-or inter-chromosomal rearrangements and mostly cytogenetically cryptic
involved cancer genes implicated in hematologic malignancy: RUNX1, IKZF1, MECOM, and MSI2.
They included RUNX1-MX1, MBNL1-MECOM, and MSI2-PRMT2. When matched CP and BP samples
from the same patient could be analyzed, some gene mutations like ASXL1, IKZF1 and SETD1B were
found to precede disease progression [96].
6. Non Genomic Loss of Tumor-Suppressor Function
In BP-CML, loss of function of key tumor suppressors may also be mediated by events not acting
at the genomic level. The best example is represented by protein phosphatase A (PP2A). PP2A is one
of the major cellular serine-threonine phosphatases and is directly involved in a multitude of cellular
processes by dephosphorylating a wide variety of key target proteins (MYC, BCL-2, MEK/ERK, AKT, RB,
JAK2, and β-catenin), hence providing a negative feedback to signals triggers and sustained by protein
kinases [97]. As such, it has been shown to negatively regulate G2 to M transition, inhibit mitogenic
signals, promote apoptosis, and interfere with WNT signaling. Inactivation of PP2A at the genetic or
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functional level has been shown to play a crucial role in cancer progression. In CML, PP2A inhibition
is accomplished mainly through the formation of an inhibitory complex with the phosphoprotein SET.
Neviani et al. have shown that, in CML BP progenitors, SET expression is markedly upregulated
by BCR-ABL1 in a dose and kinase-dependent manner via induction of hnRNP A1 [98]. Direct
phosphorylation of one of PP2A subunits by BCR-ABL1 itself or by other kinases like JAK2 or SRC
may also contribute to the suppression of its phosphatase activity. BCR-ABL1 and PP2A share several
targets. Among these, MYC, STAT5, MAPK, AKT, BAD and RB are essential for BCR-ABL1-mediated
leukemogenesis and have been found altered in BP. Indeed, in BCR-ABL1-expressing myeloid
progenitor 32Dcl3 cells, inhibition of SET expression or forced expression of PP2A decreased MYC
expression, increased the levels of proapoptotic BAD and led to inhibition of MAPK, STAT5 and AKT
phosphorylation thus inducing growth suppression, enhancing apoptosis and restoring differentiation.
Additionally, PP2A-induced activation of the SHP-1 tyrosine phosphatase has been shown to promote
BCR-ABL1 tyrosine dephosphorylation (inactivation) which, in turn, triggers its proteasome-dependent
degradation in CML BP progenitor patient cells [98].
7. Differentiation Arrest
In CML, the transition from CP to BP is characterized by a progressively increasing impairment of
myeloid blast differentiation which determines the stack of myeloid progenitors. Both BCR-ABL1-
dependent and BCR-ABL1-independent mechanisms interfering with differentiation pathways have
been described. For example, the marked downregulation of the lineage-specific transcriptor factor
CCAAT-enhancer binding protein alpha (C/EBPα) induced by high BCR-ABL1 levels plays a crucial role
in the arrest of myeloid cell development [99]. Indeed, C/EBPα expression rises with the commitment
of multipotential precursors to myeloid differentiation: its upregulation drives the granulopoiesis
while its downregulation contributes to monopoiesis [100]. As a result of genetic and epigenetic
alterations, C/EBPα activity may be repressed at different levels in myeloid leukemias. As matter
of fact, the increase in BCR-ABL1 expression, marking the transition from CP to BP, is associated
with suppression of C/EBPα expression at the translational level. Perrotti et al. showed that in
myeloid precursor 32Dcl3 cells transfected with BCR-ABL1 and in primary bone marrow cells from
individuals with CML-BP, suppression of C/EBPα protein expression is due to the interaction between
CEBPA mRNA with the RNA-binding protein hnRNP E2 [99]. hnRNP E2 and C/EBPα expressions
resulted to be inversely correlated: the first one was undetectable in normal marrow and in CML-CP
mononuclear cells, which regularly express C/EBPα. Conversely, hnRNP E2 expression was high
in CML-BP samples lacking C/EBPα [99]. hnRNP-E2 is post-translationally induced by BCR-ABL1
in a dose and kinase-dependent manner through constitutive activation. ERK1/2 phosphorylate
hnRNP-E2, increasing protein stability [101,102]. Following the observation of an inverse correlation
between miR-328 and hnRNP E2 expression and between miR-328 and BCR-ABL1 expression and
activity in CML-BP progenitors, it was later found that the BCR-ABL1/MAPK/hnRNP-E2/C/EBPα
network also involves miR-328 [103]. miR-328 was found to compete with C/EBPα mRNA for
binding to hnRNP-E2, thus interfering with hnRNP-E2-mediated inhibition of C/EBPα translation,
and to silence the expression of the pro-survival PIM1 kinase through the interaction with its 3′-UTR.
Additionally, C/EBPα was found to bind miR-328 promoter, thus enhancing its transcription. It was
thus demonstrated that BCR-ABL1 uses the MAPK/hnRNP-E2/C/EBPα pathway to suppress both
C/EBPα protein expression and miR-328 transcription [103]. Additional mechanisms acting at the
genetic level may contribute to the arrest of myeloid or lymphoid development. As detailed in the
chapters above, many recurrent mutations and copy number alterations both in myeloid and in
lymphoid BP involve transcription factors regulating myeloid (GATA2, UBE2A, RUNX1) or lymphoid
(CDKN2A, Ikaros) differentiation.
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8. Methylation Changes
Epigenetic changes are known to cooperate with genetic events in human tumorigenesis. Although
aberrant hypermethylation in CML had previously been described [104–109], the role of altered DNA
methylation in CML progression is still to be deeply investigated. There is a strong evidence that
methylation of CpG islands (CGIs) is associated with transcriptional gene silencing. In this regard,
Jelinek et al. studied the methylation status of promoter-associated CpG island of 10 genes (ABL1,
CDH13, DPYS, CDKN2B, OSCIP1, PGR-A, PGR-B, TFAP2E, NPM2, PDLIM4) in CML patients observing
a remarkable methylation increase underlying the progression from AP to BP [110]. A correlation
between an increased methylation status of these genes and resistance or intolerance to imatinib was
also found [110]. Hypermethylation of the tumor suppressor PDLIM4 was found to be a negative
prognostic factor independent from imatinib response and from CML phase [110]. Thank to the high
throughput of NGS, Heller et al. [111] investigated the methylome of CML patients in CP, AP, and
BP as compared to controls. CpG site methylation was found to increase dramatically (up to 58,691
differentially methylated CpG sites) during progression from CP to AP/BP. Interestingly, they were
able to localize the CpG sites associated with a higher methylation status in the advanced CML stages
in or around CGIs, but also in the binding sites of specific transcription factors. Taking advantage of
RNA-seq, they were also able to identify the genes that are transcriptionally regulated by methylation
in BP samples. Some of these genes were known to be implicated in the pathogenesis of various
malignancies, but their exact role in CML progression remains to be further investigated.
9. Perturbations in RNA Transcription, Editing and Translation
The increased BCR-ABL1 expression observed in BP CML has also been linked to an aberrant
regulation of processing, nuclear export and translation of mRNA. Aberrant expression of various
RNA-binding proteins (RBPs) with post-transcriptional and translational regulatory roles has been
observed in mouse models and primary blasts from CML patients. RNA-binding proteins regulate
transcription, maturation, nucleocytoplasmic transport, RNA stability and translation; some of them
are general regulators while others recognize given mRNAs in a sequence-specific manner. Besides
the already mentioned interplays between hnRNP E2 and C/EBPα, and between hnRNP-A1 and
SET/PP2A, other RBPs that have been implicated in CML progression are: HNRPK, which binds the
internal ribosome entry site (IRES) element of MYC mRNA and enhances its translation in a BCR-ABL1
and MAPK-dependent manner [101]; La/SSB, which enhances MDM2 translation contributing to p53
inactivation [112]; FUS/TLS, which binds the granulocyte colony-stimulating factor receptor (G-CSFR)
pre-mRNA in the nucleus and interferes with its processing and export [113]; and CUGBP1, whose loss
results in a reduced translation of C/EBPβ [114]. hnRNP-A1 has also been found to bind the mRNA
encoding the E2F3 transcription factor [115] leading to its upregulation in BP CML progenitors [116,117].
Different BCR-ABL1-dependent mechanisms underlie the aberrant expression and/or function of RBPs,
some of whom involve phosphorylation events by PI-3K/AKT, ERK or PKC. Overall, these phenomena
contribute to differentiation arrest and resistance to apoptosis of BP-CML progenitors by either the
loss of function of tumor suppressors, upregulation of oncogenes, or altered expression of regulatory
factors essential in differentiation processes.
There is also evidence that BCR-ABL1 interferes with the efficiency of the basal machinery
responsible for mRNA translation. The latter is accomplished via regulation of the mTOR and S6
kinase pathway and of the EIF4E e EIF4E-BP translation factors [116,117].
More recently, a massively parallel RNA sequencing approach has revealed an increased expression
of the adenosine deaminase acting on dsRNA-1 (ADAR-1) in progenitor cells obtained from primary
BP CML patient samples. ADAR-1 performs adenosine to inosine (A to I) RNA editing of double strand
RNA hairpins formed between Alu repetitive elements, thus altering mRNA structure, generating or
abolishing donor and acceptor splice sites and introducing sequence alterations. Functional studies
demonstrated that ADAR-1-mediated RNA editing plays a role in the malignant reprogramming of
myeloid progenitors into LSC that drive CML progression, by promoting the expression of the myeloid
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transcription factor PU.1 and producing misspliced isoforms of GSK3β [118]. The increased expression
and activity of ADAR-1 was found to be mediated by inflammatory cytokine-activated JAK/STAT
signaling as well as by BCR-ABL1 signaling [119]. Other ADAR-1 targets were found to be MDM2,
APOBEC3D, GLI1 and AZIN [120] and the miRNA Let-7 [119]. In particular, ADAR-1 hyper-editing of
the 3′-UTR of MDM2 prevents miRNA binding, thus resulting in increased MDM2 expression and
repression of the p53 tumor suppressor [118].
10. The Role of MicroRNAs
MicroRNAs (miRNAs) are known to play an essential role in tumorigenesis [121–123] by
post-transcriptional regulation of gene expression. Aberrant expression of several miRNAs has
been described in CML, in association with stem cell survival and self-renewal, sensitivity or resistance
to TKI therapy, and disease progression. In the latter context, a microarray analysis revealed differential
expression profiles of several miRNAs–namely, the up-regulation of miR-19a, miR-19b, miR-17,
miR-20a, miR-92a, miR-221, miR-222, miR-126, miR-146a, miR-181a, miR-181b, let7c, and miR-155 and
the down-regulation of miR-150, miR-452, miR-103, and miR-144–in BP samples [124]. The association
between reduced miR-150 level, myeloid differentiation block and resistance to TKIs was later found
to be due to a novel mechanism whereby BCR-ABL1 recruits MYC to bind and inhibit miR-150
expression [125].
As previously mentioned, another key miRNA is miR-328, that is involved in C/EBPαdownregulation
and in the subsequent block of myeloid differentiation [99,103].
11. Metabolic Changes
All cancer cells develop an altered metabolism to support their growth and survival. Recently, it
has been suggested that increased branched chain amino acid (BCAAs; valine, leucine, and isoleucine)
metabolism may contribute to disease progression in CML. Following the observation that mice with
BP CML display higher levels of proline and BCAAs, Hattori et al. found a significant upregulation of
branched chain amino acid aminotransferase 1 (BCAT1) at the mRNA and protein levels in BP-CML as
compared to CP-CML or healthy mice [126]. Similarly, patients with BP-CML showed higher BCAT1
expression as compared to CP CML patients. BCAT1 is a cytosolic aminotransferase that may generate
BCAAs from branched chain ketoacids. BCAAs, particularly leucine, activate the mTORC1 pathway,
which promotes cell growth as a result of the integration of nutrient sensing, energy status, stress and
growth factors [127]. BCAT1 upregulation was found to result from association with Musashi 2 (Msi2),
an oncogenic RNA binding protein that post-transcriptionally regulates gene expression and that was
already known to be upregulated and to cooperate in disease progression via repression of the cell fate
regulator Numb [128,129].
12. TKI Resistance and LSC Persistence: Two Sides of the Same Coin?
Three levels of response to therapy are routinely defined in CML: hematological response,
cytogenetic response (reduction in the percentage of BM metaphases positive for the Philadelphia
chromosome) and molecular response (reduction in BCR-ABL1 transcript levels, measured in terms
of logarithmic reduction from a standardized baseline) [30,130]. Nowadays, the term ‘’resistance” is
used to label a wide and heterogeneous spectrum of ‘’non optimal” levels of response to TKI therapy
ranging from failure to achieve a major molecular response (MMR; defined as BCR-ABL1 transcript
levels at or below 0.1%) or increase in BCR-ABL1 transcript levels leading to a loss of MMR, to a
frank loss of hematological response. This is essentially due to the fact that patients’ and physicians’
expectations regarding treatment endpoints have increased greatly since the advent of TKIs. If, in the
early days of the imatinib era, the endpoints were still ‘limited’ to improving the overall survival and
delaying disease progression, it was soon realized that molecular responses could be achieved in a
significant proportion of patients and correlated with superior outcomes (hence the definition of MMR
as ‘’safe haven”) [131]. More recently, the endpoint has become even more ambitious—deep molecular
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response (DMR; defined as BCR-ABL1 transcript levels at or below 0.01%), because it correlates with
optimal long term survival outcomes and because it is the pre-requisite for treatment discontinuation.
The fact that very low levels of residual disease may still be detected after many years of therapy in a
not negligible proportion of patients, and that even when molecularly undetectable the disease may
often re-emerge after TKI discontinuation is referred to as ‘’persistence”. The mechanisms responsible
for resistance are likely to be at least in part different from those underlying disease persistence at the
molecular level. Resistance mechanisms have extensively been reviewed elsewhere [132–134]. In an
attempt to fill the gaps in knowledge about BCR-ABL1-independent mechanisms that may enable Ph+
cells to survive despite TKI-mediated BCR-ABL1 inhibition, recent research studies have highlighted a
number of pathways/molecules that might also be therapeutically targeted (summarized in Table 1).
Table 1. Overview of the molecules and pathways that have been implicated in BCR-ABL1-
independent resistance.
Gene/Pathway Ref Druggable?
PI3K/AKT/mTOR Burchert, Leukemia 2005 [135] PI3K/mTOR inhibitors
Lyn Wu et al., Blood 2008 [136] Src inhibitors
Autophagy Bellodi et al., J Clin Invest 2009 [137] hydroxychloroquine
SHP-1 Esposito et al., Blood 2011 [138] X
SIRT1 Wang et al., Oncogene 2013 [139] selisistat
PRKCH Ma et al., Sci Transl Med 2014 [140] MEK inh (trametinib) + Imatinib
STAT3 Eiring et al., Leukemia 2015 [141] BP-5-087
CRM1/XPO1/RAN Khorashad et al., Blood 2015 [142]Walker et al., Blood 2016 [143] selinexor
JAK2 Chakraborty et al., Genes Cancer 2016 [144] ruxolitinib
FOXO1 Wagle et al., Leukemia 2016 [145] PI3K inhibitors
EZH2 Scott et al., Cancer Discov 2016 [146] EZH2 inhibitors
Wnt/b catenin Eiring et al., Leukemia 2015 [141],Zhou et al., Leukemia 2017 [147] C82
MS4A3 Eiring et al., ASH 2017 [148] X
PFKFB3 Zhu et al., Oncogene 2018 [149] PFK-158
Various miRNAs X
Persistence is thought to be mainly attributable to the fact that TKIs may eliminate differentiated
and progenitor cells, but spare LSCs. BCR-ABL1-positive primitive cells are indeed detectable in the
BM in patients with MMR and even DMR [150–154]. The fact that LSCs are intrinsically insensitive to
TKIs was observed early after the introduction of first and second-generation TKIs [150,155–157]. Later
on, a series of experiments in cell lines and mouse models suggested that LSC are not dependent from
BCR-ABL1 kinase activity for their survival, and that BCR-ABL1 may possess non kinase-mediated
functions influencing signaling pathways responsible for LSC survival [157–160]. It has also been
hypothesized that while BCR-ABL1 expression is high in pre-therapy CD34+ cells, TKIs select for CML
precursors with low BCR-ABL1 expression and signaling, hence less oncogene-addicted [161,162]. This
has sparked searches for LSC-selective BCR-ABL1 kinase-independent pathways. To date, a number of
cell- intrinsic and cell extrinsic pathways and mechanisms have been suggested to contribute to the
TKI-resistant LSC phenotype, and many of them are potentially druggable. Among the cell-intrinsic
mechanisms, Foxo [163,164], Sonic Hedgehog [165,166] and Wnt/β-catenin [167,168] pathways are
the most extensively investigated ones. However, interaction with the BM microenvironment is
thought to be equally critical for LSC survival. CD44/E-selectin [169,170], galectin-3 (Gal-3) [171],
CXCR4/CXCL12 [172] have all been suggested to enhance LSC self-renewal. Last but not least, it has
been hypothesized that modulation of host immune surveillance in the BM microenvironment may
have a role in preventing LSC eradication. In this regard, cytotoxic T lymphocytes exhaustion via
interaction of the PD-1 receptor expressed on cytotoxic T lymphocytes with its inhibitory ligand
PD-L1 expressed on CML cells has been observed [173,174]. Cytokine-mediated downregulation of
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Major Histocompatibility Complex class II (MHC-II) molecule expression has been reported to be an
alternative way for LSCs to evade immune surveillance [175]. All these mechanisms are summarized
in Figure 3.
Figure 3. Persistence of LSCs: BCR-ABL1 kinase-dependent and -independent pathways.
Schematic representation of the key pathways and molecules known to be implicated in LSC
persistence in CML. a) Foxo3a plays a key role in the TGF-β signalling pathway driving the survival of
leukemia initiating cells (LICs) during TKI treatment. In LICs, despite BCR-ABL1 expression in all
CML cells, Akt is inactivated and as consequence, the Foxo proteins are retained in an active form in
the nucleus inducing transcription and maintenance of LSCs. TGF-β signalling is activated in CML
LICs, where it controls Foxo localization.
b) In the Sonic/Hedgehog pathway, Smo is upregulated in BCR-ABL1-positive LSCs. On the
other hand, it is not necessary for the long-term regeneration of LSCs. c) BCR-ABL1-positive LSCs
are more dependent from an higher expression of CD44 for homing and engraftment as compared to
the HSCs. d) Reduced CXCL12 expression in BM stromal cells determines an impaired LSC homing
and BM retention. e) High levels of Gal-3 expression in BM support disease maintanence, multidrug
resistance to TKIs and long-term BM lodgment of CML cells. f) Expression of β-catenin in LSCs
determines an increased growth and a reduced differentiation. g) The interaction between the PD-1
receptor expressed on CTLs and the inhibitory ligand PD-L1 present on CML cells enables the latter to
escape from immune surveillance. h) The antitumor-associated immune response exercised by CD4+
T helper cells is prevented by the downregulation of the MHCII. Abbrevations: LSC (leukemia stem
cell), OB (osteoblast), OC (osteoclast), SC (staminal cell), HSC (hematopoietic stem cell), CTL (cytotoxic
T lymphocyte), LIC (leukemia initiating cell).
13. Conclusions and Future Perspectives
Though rare, resistance to TKI therapy and disease progression remain a concern for physicians
and patients. Whenever resistance occurs, reactivation of BCR-ABL1 kinase activity represents a
“fire under the ashes” that may ultimately lead to the evolution from CP to BP—which represents a
clinical emergence even in the era of TKIs. The lack of a unifying path of disease progression and the
profound molecular heterogeneity of BP CML patients limit the effectiveness of therapeutic options
once BP is diagnosed—which strongly underline the importance of preventing rather than treating
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progression. High risk patients may be identified using scores like Sokal or EUTOS [3]. Major route
ACAs may also help identify patients at greater risk of progression [53]. Some biological factors have
also been proposed in single studies (e.g., germline variants in ASXL1 and BIM genes [176,177]; CIP2A
protein levels at diagnosis [178]). So far, however, no validated prediction algorithm has ever been
derived that may soundly predict who will develop BP. Thus, strict MR monitoring and thoughtful
TKI therapy reassessment in case of failure to achieve the key response milestones are currently the
only way to minimize the risk of progression.
Even in patients achieving deep molecular responses to TKI therapy, LSCs have been reported
to persist, constituting a dangerous reservoir that may feed disease recurrence in case of treatment
discontinuation. Twenty years of research have resulted in a wealth of biological acquisitions. However,
very few clinical trials evaluating the combination of TKIs with agents aimed at selectively targeting LSC
are underway [179]. Hence it is currently difficult to predict whether a successful and well-tolerated
eradication strategy will ever be defined.
Funding: This research received no external funding.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Faderl, S.; Talpaz, M.; Estrov, Z.; O’Brien, S.; Kurzrock, R.; Kantarjian, H.M. The biology of chronic myeloid
leukemia. N. Engl. J. Med. 1999, 341, 164–172. [CrossRef] [PubMed]
2. Bruns, I.; Czibere, A.; Fischer, J.C.; Roels, F.; Cadeddu, R.P.; Buest, S.; Bruennert, D.; Huenerlituerkoglu, A.N.;
Stoecklein, N.H.; Singh, R. The hematopoietic stem cell in chronic phase CML is characterized by a
transcriptional profile resembling normal myeloid progenitor cells and reflecting loss of quiescence. Leukemia
2009, 23, 892. [CrossRef] [PubMed]
3. Baccarani, M.; Deininger, M.W.; Rosti, G.; Hochhaus, A.; Soverini, S.; Apperley, J.F.; Cervantes, F.; Clark, R.E.;
Cortes, J.E.; Guilhot, F. European LeukemiaNet recommendations for the management of chronic myeloid
leukemia: 2013. Blood 2013, 122, 872–884. [CrossRef] [PubMed]
4. Ch’ang, H.-J.; Tien, H.-F.; Wang, C.-H.; Chuang, S.-M.; Chen, Y.C.; Shen, M.-C.; Lin, D.-T.; Lin, K.-H.
Comparison of clinical and biologic features between myeloid and lymphoid transformation of Philadelphia
chromosome positive chronic myeloid leukemia. Cancer Genet. Cytogenet. 1993, 71, 87–93. [CrossRef]
5. Jaffe, E.S.; Harris., N.L.; Stein, H.; Vardiman, J.W. Pathology and Genetics of Tumours of Haematopoietic and
Lymphoid Tissues, WHO Classification of Tumours, 3rd ed.; IARC Press: Lyon, France, 2001; Volume 3.
6. Reid, A.G.; De Melo, V.A.; Elderfield, K.; Clark, I.; Marin, D.; Apperley, J.; Naresh, K.N. Phenotype of blasts
in chronic myeloid leukemia in blastic phase—Analysis of bone marrow trephine biopsies and correlation
with cytogenetics. Leuk. Res. 2009, 33, 418–425. [CrossRef] [PubMed]
7. Dorfman, D.M.; Longtine, J.A.; Fox, E.A.; Weinberg, D.S.; Pinkus, G.S. T-cell blast crisis in chronic myelogenous
leukemia: Immunophenotypic and molecular biologic findings. Am. J. Clin. Pathol. 1997, 107, 168–176.
[CrossRef] [PubMed]
8. Schoch, C.; Haferlach, T.; Kern, W.; Schnittger, S.; Berger, U.; Hehlmann, R.; Hiddemann, W.; Hochhaus, A.
Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib
mesylate. Leukemia 2003, 17, 461. [CrossRef]
9. Gozzetti, A.; Bocchia, M.; Calabrese, S.; Pirrotta, M.T.; Crupi, R.; Raspadori, D.; Lauria, F. Promyelocytic
blast crisis of chronic myelogenous leukemia during imatinib treatment. Acta Haematol. 2007, 117, 236–237.
[CrossRef]
10. Angriman, F.; Gutierrez Acevedo, M.N.; Rossi, M.S.; Gimenez Conca, A.D.; Otero, V.; Arbelbide, J.A.;
Michelangelo, H. Promyelocytic Blastic Crisis in Chronic Myeloid Leukemia during Imatinib Treatment.
Turk. J. Haematol. 2015, 32, 193–194. [CrossRef]
11. Radich, J.P.; Dai, H.; Mao, M.; Oehler, V.; Schelter, J.; Druker, B.; Sawyers, C.; Shah, N.; Stock, W.; Willman, C.L.
Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc. Natl.
Acad. Sci. USA 2006, 103, 2794–2799. [CrossRef]
12. Cortes, J.E.; Saglio, G.; Kantarjian, H.M.; Baccarani, M.; Mayer, J.; Boqué, C.; Shah, N.P.; Chuah, C.;
Casanova, L.; Bradley-Garelik, B. Final 5-year study results of DASISION: The dasatinib versus imatinib
Int. J. Mol. Sci. 2019, 20, 6141 14 of 23
study in treatment-naïve chronic myeloid leukemia patients trial. J. Clin. Oncol. 2016, 34, 2333. [CrossRef]
[PubMed]
13. Hochhaus, A.; Saglio, G.; Hughes, T.P.; Larson, R.A.; Kim, D.W.; Issaragrisil, S.; Le Coutre, P.D.; Etienne, G.;
Dorlhiac-Llacer, P.E.; Clark, R.E. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic
myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia 2016, 30,
1044. [CrossRef] [PubMed]
14. Cortes, J.E.; Gambacorti-Passerini, C.; Deininger, M.W.; Mauro, M.J.; Chuah, C.; Kim, D.-W.; Dyagil, I.;
Glushko, N.; Milojkovic, D.; le Coutre, P. Bosutinib versus imatinib for newly diagnosed chronic myeloid
leukemia: Results from the randomized BFORE trial. J. Clin. Oncol. 2018, 36, 231. [CrossRef] [PubMed]
15. Jain, P.; Kantarjian, H.M.; Ghorab, A.; Sasaki, K.; Jabbour, E.J.; Nogueras Gonzalez, G.; Kanagal-Shamanna, R.;
Issa, G.C.; Garcia-Manero, G.; Dellasala, S.; et al. Prognostic factors and survival outcomes in patients with
chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.
Cancer 2017, 123, 4391–4402. [CrossRef] [PubMed]
16. Jamieson, C.H.M.; Ailles, L.E.; Dylla, S.J.; Muijtjens, M.; Jones, C.; Zehnder, J.L.; Gotlib, J.; Li, K.; Manz, M.G.;
Keating, A. Granulocyte–macrophage progenitors as candidate leukemic stem cells in blast-crisis CML.
N. Engl. J. Med. 2004, 351, 657–667. [CrossRef] [PubMed]
17. Minami, Y.; Stuart, S.A.; Ikawa, T.; Jiang, Y.; Banno, A.; Hunton, I.C.; Young, D.J.; Naoe, T.; Murre, C.;
Jamieson, C.H.M. BCR-ABL-transformed GMP as myeloid leukemic stem cells. Proc. Natl. Acad. Sci. USA
2008, 105, 17967–17972. [CrossRef]
18. Nakahara, F.; Sakata-Yanagimoto, M.; Komeno, Y.; Kato, N.; Uchida, T.; Haraguchi, K.; Kumano, K.;
Harada, Y.; Harada, H.; Kitaura, J. Hes1 immortalizes committed progenitors and plays a role in blast crisis
transition in chronic myelogenous leukemia. Blood 2010, 115, 2872–2881. [CrossRef]
19. Wetzler, M.; Talpaz, M.; Van Etten, R.A.; Hirsh-Ginsberg, C.; Beran, M.; Kurzrock, R. Subcellular localization
of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid
differentiation. J. Clin. Invest. 1993, 92, 1925–1939. [CrossRef]
20. Gaiger, A.; Henn, T.; Horth, E.; Geissler, K.; Mitterbauer, G.; Maier-Dobersberger, T.; Greinix, H.;
Mannhalter, C.; Haas, O.A.; Lechner, K. Increase of bcr-abl chimeric mRNA expression in tumor cells
of patients with chronic myeloid leukemia precedes disease progression. Blood 1995, 86, 2371–2378.
[CrossRef]
21. Elmaagacli, A.H.; Beelen, D.W.; Opalka, B.; Seeber, S.; Schaefer, U.W. The amount of BCR-ABL fusion
transcripts detected by the real-time quantitative polymerase chain reaction method in patients with
Philadelphia chromosome positive chronic myeloid leukemia correlates with the disease stage. Ann. Hematol.
2000, 79, 424–431. [CrossRef]
22. Hosoya, N.; Sanada, M.; Nannya, Y.; Nakazaki, K.; Wang, L.; Hangaishi, A.; Kurokawa, M.; Chiba, S.;
Ogawa, S. Genomewide screening of DNA copy number changes in chronic myelogenous leukemia with the
use of high-resolution array-based comparative genomic hybridization. Genes Chromosom. Cancer 2006, 45,
482–494. [CrossRef] [PubMed]
23. Brazma, D.; Grace, C.; Howard, J.; Melo, J.V.; Holyoke, T.; Apperley, J.F.; Nacheva, E.P. Genomic profile of
chronic myelogenous leukemia: Imbalances associated with disease progression. Genes Chromosom. Cancer
2007, 46, 1039–1050. [CrossRef] [PubMed]
24. Nowak, D.; Ogawa, S.; Müschen, M.; Kato, M.; Kawamata, N.; Meixel, A.; Nowak, V.; Kim, H.S.; Kang, S.;
Paquette, R. SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid leukemia identifies
heterogeneous secondary genomic alterations. Blood 2010, 115, 1049–1053. [CrossRef] [PubMed]
25. Nadarajan, V.S.; Phan, C.-L.; Ang, C.-H.; Liang, K.-L.; Gan, G.-G.; Bee, P.-C.; Zakaria, Z. Identification of copy
number alterations by array comparative genomic hybridization in patients with late chronic or accelerated
phase chronic myeloid leukemia treated with imatinib mesylate. Int. J. Hematol. 2011, 93, 465–473. [CrossRef]
[PubMed]
26. Lee, S.-T.; Ji, Y.; Kim, H.-J.; Ki, C.-S.; Jung, C.W.; Kim, J.-W.; Kim, S.-H. Sequential array comparative genomic
hybridization analysis identifies copy number changes during blastic transformation of chronic myeloid
leukemia. Leuk. Res. 2012, 36, 418–421. [CrossRef]
27. van der Sligte, N.E.; Krumbholz, M.; Pastorczak, A.; Scheijen, B.; Tauer, J.T.; Nowasz, C.; Sonneveld, E.;
de Bock, G.H.; Meeuwsen-de Boer, T.G.J.; van Reijmersdal, S. DNA copy number alterations mark disease
progression in paediatric chronic myeloid leukaemia. Br. J. Haematol. 2014, 166, 250–253. [CrossRef]
Int. J. Mol. Sci. 2019, 20, 6141 15 of 23
28. Antoszewska-Smith, J.; Pawlowska, E.; Błasiak, J. Reactive oxygen species in BCR-ABL1-expressing
cells–relevance to chronic myeloid leukemia. Acta Biochim. Pol. 2017, 64, 1–10. [CrossRef]
29. Sattler, M.; Verma, S.; Shrikhande, G.; Byrne, C.H.; Pride, Y.B.; Winkler, T.; Greenfield, E.A.; Salgia, R.;
Griffin, J.D. The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic
cells. J. Biol. Chem. 2000, 275, 24273–24278. [CrossRef]
30. Koptyra, M.; Falinski, R.; Nowicki, M.O.; Stoklosa, T.; Majsterek, I.; Nieborowska-Skorska, M.; Blasiak, J.;
Skorski, T. BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance.
Blood 2006, 108, 319–327. [CrossRef]
31. Nowicki, M.O.; Falinski, R.; Koptyra, M.; Slupianek, A.; Stoklosa, T.; Gloc, E.; Nieborowska-Skorska, M.;
Blasiak, J.; Skorski, T. BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen
species–dependent DNA double-strand breaks. Blood 2004, 104, 3746–3753. [CrossRef]
32. Pastink, A.; Eeken, J.C.J.; Lohman, P.H.M. Genomic integrity and the repair of double-strand DNA breaks.
Mutat. Res. Mol. Mech. Mutagen. 2001, 480, 37–50. [CrossRef]
33. Deutsch, E.; Jarrousse, S.; Buet, D.; Dugray, A.; Bonnet, M.-L.; Vozenin-Brotons, M.-C.; Guilhot, F.; Turhan, A.G.;
Feunteun, J.; Bourhis, J. Down-regulation of BRCA1 in BCR-ABL–expressing hematopoietic cells. Blood 2003,
101, 4583–4588. [CrossRef] [PubMed]
34. Podszywalow-Bartnicka, P.; Wolczyk, M.; Kusio-Kobialka, M.; Wolanin, K.; Skowronek, K.;
Nieborowska-Skorska, M.; Dasgupta, Y.; Skorski, T.; Piwocka, K. Downregulation of BRCA1 protein in
BCR-ABL1 leukemia cells depends on stress-triggered TIAR-mediated suppression of translation. Cell Cycle
2014, 13, 3727–3741. [CrossRef] [PubMed]
35. Dkhissi, F.; Aggoune, D.; Pontis, J.; Sorel, N.; Piccirilli, N.; LeCorf, A.; Guilhot, F.; Chomel, J.-C.; Ait-Si-Ali, S.;
Turhan, A.G. The downregulation of BAP1 expression by BCR-ABL reduces the stability of BRCA1 in chronic
myeloid leukemia. Exp. Hematol. 2015, 43, 775–780. [CrossRef] [PubMed]
36. Pannunzio, N.R.; Watanabe, G.; Lieber, M.R. Nonhomologous DNA end-joining for repair of DNA
double-strand breaks. J. Biol. Chem. 2018, 293, 10512–10523. [CrossRef] [PubMed]
37. Sallmyr, A.; Tomkinson, A.E.; Rassool, F.V. Up-regulation of WRN and DNA ligase IIIα in chronic myeloid
leukemia: Consequences for the repair of DNA double-strand breaks. Blood 2008, 112, 1413–1423. [CrossRef]
38. Slupianek, A.; Poplawski, T.; Jozwiakowski, S.K.; Cramer, K.; Pytel, D.; Stoczynska, E.; Nowicki, M.O.;
Blasiak, J.; Skorski, T. BCR/ABL stimulates WRN to promote survival and genomic instability. Cancer Res.
2011, 71, 842–851. [CrossRef]
39. Wada, C.; Shionoya, S.; Fujino, Y.; Tokuhiro, H.; Akahoshi, T.; Uchida, T.; Ohtani, H. Genomic instability of
microsatellite repeats and its association with the evolution of chronic myelogenous leukemia [see comments].
Blood 1994, 83, 3449–3456. [CrossRef]
40. Slupianek, A.; Falinski, R.; Znojek, P.; Stoklosa, T.; Flis, S.; Doneddu, V.; Pytel, D.; Synowiec, E.; Blasiak, J.;
Bellacosa, A. BCR-ABL1 kinase inhibits uracil DNA glycosylase UNG2 to enhance oxidative DNA damage
and stimulate genomic instability. Leukemia 2013, 27, 629. [CrossRef]
41. Alhuraiji, A.; Kantarjian, H.; Boddu, P.; Ravandi, F.; Borthakur, G.; DiNardo, C.; Daver, N.; Kadia, T.;
Pemmaraju, N.; Pierce, S. Prognostic significance of additional chromosomal abnormalities at the time of
diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors. Am. J.
Hematol. 2018, 93, 84–90. [CrossRef]
42. Kantarjian, H.M.; Smith, T.L.; McCredie, K.B.; Keating, M.J.; Walters, R.S.; Talpaz, M.; Hester, J.P.; Bligham, G.;
Gehan, E.; Freireich, E.J. Chronic myelogenous leukemia: A multivariate analysis of the associations of
patient characteristics and therapy with survival. Blood 1985, 66, 1326–1335. [CrossRef]
43. Sokal, J.E.; Gomez, G.A.; Baccarani, M.; Tura, S.; Clarkson, B.D.; Cervantes, F.; Rozman, C.; Carbonell, F.;
Anger, B.; Heimpel, H. Prognostic significance of additional cytogenetic abnormalities at diagnosis of
Philadelphia chromosome-positive chronic granulocytic leukemia. Blood 1988, 72, 294–298. [CrossRef]
44. Marktel, S.; Marin, D.; Foot, N.; Szydlo, R.; Bua, M.; Karadimitris, A.; De Melo, V.A.; Kotzampaltiris, P.;
Dazzi, F.; Rahemtulla, A. Chronic myeloid leukemia in chronic phase responding to imatinib: The occurrence
of additional cytogenetic abnormalities predicts disease progression. Haematologica 2003, 88, 260–267.
45. Ishihara, T.; Sasaki, M.; Oshimura, M.; Kamada, N.; Yamada, K.; Okada, M.; Sakurai, M.; Sugiyama, T.;
Shiraishi, Y.; Kohno, S.; et al. A summary of cytogenetic studies on 534 cases of chronic myelocytic leukemia
in Japan. Cancer Genet. Cytogenet. 1983, 9, 81–91. [CrossRef]
Int. J. Mol. Sci. 2019, 20, 6141 16 of 23
46. Swolin, B.; Weinfeld, A.; Westin, J.; Waldenström, J.; Magnusson, B. Karyotypic evolution in Ph-positive
chronic myeloid leukemia in relation to management and disease progression. Cancer Genet. Cytogenet. 1985,
18, 65–79. [CrossRef]
47. Krulik, M.; Smadja, N.; De Gramont, A.; Gonzalez-Canali, G.; Audebert, A.A.; Dray, C.; Brissaud, P.;
Debray, J. Sequential karyotype study on Ph-positive chronic myelocytic leukemia. Significance of additional
chromosomal abnormalities during disease evolution. Cancer Genet. Cytogenet. 1987, 60, 974–979. [CrossRef]
48. Mitelman, F.; Levan, G.; Nilsson, P.G.; Brandt, L. Non-random karyotypic evolution in chronic myeloid
leukemia. Int. J. Cancer 1976, 18, 24–30. [CrossRef]
49. Mitelman, F. The cytogenetic scenario of chronic myeloid leukemia. Leuk. Lymphoma 1993, 11, 11–15.
[CrossRef]
50. Cortes, J.E.; Talpaz, M.; Giles, F.; O’Brien, S.; Rios, M.B.; Shan, J.; Garcia-Manero, G.; Faderl, S.; Thomas, D.A.;
Wierda, W. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous
leukemia on imatinib mesylate therapy. Blood 2003, 101, 3794–3800. [CrossRef]
51. Lippert, E.; Etienne, G.; Mozziconacci, M.-J.; Laibe, S.; Gervais, C.; Girault, S.; Gachard, N.; Tigaud, I.;
Dastugue, N.; Huguet, F. Loss of the Y chromosome in Philadelphia-positive cells predicts a poor response
of chronic myeloid leukemia patients to imatinib mesylate therapy. Haematologica 2010, 95, 1604–1607.
[CrossRef]
52. Luatti, S.; Castagnetti, F.; Marzocchi, G.; Baldazzi, C.; Gugliotta, G.; Iacobucci, I.; Specchia, G.; Zanatta, L.;
Rege-Cambrin, G.; Mancini, M. Additional chromosomal abnormalities in Philadelphia-positive clone:
Adverse prognostic influence on frontline imatinib therapy: A GIMEMA Working Party on CML analysis.
Blood 2012, 120, 761–767. [CrossRef] [PubMed]
53. Fabarius, A.; Leitner, A.; Hochhaus, A.; Müller, M.C.; Hanfstein, B.; Haferlach, C.; Göhring, G.;
Schlegelberger, B.; Jotterand, M.; Reiter, A. Impact of additional cytogenetic aberrations at diagnosis
on prognosis of CML: Long-term observation of 1151 patients from the randomized CML Study IV. Blood
2011, 118, 6760–6768. [CrossRef] [PubMed]
54. Wang, W.; Cortes, J.E.; Tang, G.; Khoury, J.D.; Wang, S.; Bueso-Ramos, C.E.; DiGiuseppe, J.A.; Chen, Z.;
Kantarjian, H.M.; Medeiros, L.J. Risk stratification of chromosomal abnormalities in chronic myelogenous
leukemia in the era of tyrosine kinase inhibitor therapy. Blood 2016, 127, 2742–2750. [CrossRef] [PubMed]
55. Chandran, R.K.; Geetha, N.; Sakthivel, K.M.; Aswathy, C.G.; Gopinath, P.; Raj, T.V.A.; Priya, G.; Nair, J.K.K.M.;
Sreedharan, H. Genomic amplification of BCR-ABL1 fusion gene and its impact on the disease progression
mechanism in patients with chronic myelogenous leukemia. Gene 2019, 686, 85–91. [CrossRef] [PubMed]
56. Johansson, B.; Fioretos, T.; Billström, R.; Mitelman, F. Aberrant cytogenetic evolution pattern of
Philadelphia-positive chronic myeloid leukemia treated with interferon-α. Leukemia 1996, 10, 1134–1138.
57. Serra, A.; Gottardi, E.; Della Ragione, F.; Saglio, G.; Iolascon, A. Involvement of the cyclin-dependent kinase-4
inhibitor (CDKN2) gene in the pathogenesis of lymphoid blast crisis of chronic myelogenous leukaemia.
Br. J. Haematol. 1995, 91, 625–629. [CrossRef]
58. Jabbour, E.; Kantarjian, H.; Jones, D.; Talpaz, M.; Bekele, N.; O’brien, S.; Zhou, X.; Luthra, R.; Garcia-Manero, G.;
Giles, F. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia
treated with imatinib mesylate. Leukemia 2006, 20, 1767. [CrossRef]
59. Soverini, S.; Colarossi, S.; Gnani, A.; Rosti, G.; Castagnetti, F.; Poerio, A.; Iacobucci, I.; Amabile, M.;
Abruzzese, E.; Orlandi, E. Contribution of ABL kinase domain mutations to imatinib resistance in different
subsets of Philadelphia-positive patients: By the GIMEMA Working Party on Chronic Myeloid Leukemia.
Clin. Cancer Res. 2006, 12, 7374–7379. [CrossRef]
60. Shah, N.P.; Skaggs, B.J.; Branford, S.; Hughes, T.P.; Nicoll, J.M.; Paquette, R.L.; Sawyers, C.L. Sequential ABL
kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic
potency. J. Clin. Invest. 2007, 117, 2562–2569. [CrossRef]
61. Stagno, F.; Stella, S.; Berretta, S.; Massimino, M.; Antolino, A.; Giustolisi, R.; Messina, A.; Di Raimondo, F.;
Vigneri, P. Sequential mutations causing resistance to both Imatinib Mesylate and Dasatinib in a chronic
myeloid leukaemia patient progressing to lymphoid blast crisis. Leuk. Res. 2008, 32, 673–674. [CrossRef]
62. Khorashad, J.S.; Kelley, T.W.; Szankasi, P.; Mason, C.C.; Soverini, S.; Adrian, L.T.; Eide, C.A.; Zabriskie, M.S.;
Lange, T.; Estrada, J.C. BCR-ABL1 compound mutations in tyrosine kinase inhibitor–resistant CML: Frequency
and clonal relationships. Blood 2013, 121, 489–498. [CrossRef]
Int. J. Mol. Sci. 2019, 20, 6141 17 of 23
63. Soverini, S.; Bavaro, L.; Martelli, M.; De Benedittis, C.; Iurlo, A.; Orofino, N.; Pagano, L.; Criscuolo, M.;
Bonifacio, M.; Scaffidi, L. Compound BCR-ABL1 Kinase Domain Mutants: Prevalence, Spectrum
and Correlation with Tyrosine Kinase Inhibitor Resistance in a Prospective Series of Philadelphia
Chromosome-Positive Leukemia Patients Analyzed By Next Generation Sequencing. Blood 2018, 132,
789. [CrossRef]
64. Zabriskie, M.S.; Eide, C.A.; Tantravahi, S.K.; Vellore, N.A.; Estrada, J.; Nicolini, F.E.; Khoury, H.J.; Larson, R.A.;
Konopleva, M.; Cortes, J.E. BCR-ABL1 compound mutations combining key kinase domain positions confer
clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell 2014, 26, 428–442. [CrossRef]
[PubMed]
65. Ahuja, H.; Bar-Eli, M.; Advani, S.H.; Benchimol, S.; Cline, M.J. Alterations in the p53 gene and the clonal
evolution of the blast crisis of chronic myelocytic leukemia. Proc. Natl. Acad. Sci. USA 1989, 86, 6783–6787.
[CrossRef] [PubMed]
66. Feinstein, E.; Cimino, G.; Gale, R.P.; Alimena, G.; Berthier, R.; Kishi, K.; Goldman, J.; Zaccaria, A.; Berrebi, A.;
Canaani, E. p53 in chronic myelogenous leukemia in acute phase. Proc. Natl. Acad. Sci. USA 1991, 88,
6293–6297. [CrossRef] [PubMed]
67. Skorski, T.; Nieborowska-Skorska, M.; Wlodarski, P.; Perrotti, D.; Martinez, R.; Wasik, M.A.; Calabretta, B.
Blastic transformation of p53-deficient bone marrow cells by p210bcr/abl tyrosine kinase. Proc. Natl. Acad.
Sci. USA 1996, 93, 13137–13142. [CrossRef]
68. Honda, H.; Ushijima, T.; Wakazono, K.; Oda, H.; Tanaka, Y.; Aizawa, S.; Ishikawa, T.; Yazaki, Y.;
Hirai, H. Acquired loss of p53 induces blastic transformation in p210 bcr/abl-expressing hematopoietic cells:
A transgenic study for blast crisis of human CML. Blood 2000, 95, 1144–1150. [CrossRef]
69. Wendel, H.-G.; de Stanchina, E.; Cepero, E.; Ray, S.; Emig, M.; Fridman, J.S.; Veach, D.R.; Bornmann, W.G.;
Clarkson, B.; McCombie, W.R. Loss of p53 impedes the antileukemic response to BCR-ABL inhibition.
Proc. Natl. Acad. Sci. USA 2006, 103, 7444–7449. [CrossRef]
70. Ahuja, H.G.; Jat, P.S.; Foti, A.; Bar-Eli, M.; Cline, M.J. Abnormalities of the retinoblastoma gene in the
pathogenesis of acute leukemia. Blood 1991, 78, 3259–3268. [CrossRef]
71. Beck, Z.; Kiss, A.; Tóth, F.D.; Szabó, J.; Bácsi, A.; Balogh, E.; Borbély, Á.; Telek, B.; Kovács, E.; Oláh, É.
Alterations of P53 and RB genes and the evolution of the accelerated phase of chronic myeloid leukemia.
Leuk. Lymphoma 2000, 38, 587–597. [CrossRef]
72. Roche-Lestienne, C.; Deluche, L.; Corm, S.; Tigaud, I.; Joha, S.; Philippe, N.; Geffroy, S.; Laï, J.-L.; Nicolini, F.-E.;
Preudhomme, C. RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+
leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and
imatinib resistance. Blood 2008, 111, 3735–3741. [CrossRef] [PubMed]
73. Zhao, L.-J.; Wang, Y.-Y.; Li, G.; Ma, L.-Y.; Xiong, S.-M.; Weng, X.-Q.; Zhang, W.-N.; Wu, B.; Chen, Z.; Chen, S.-J.
Functional features of RUNX1 mutants in acute transformation of chronic myeloid leukemia and their
contribution to inducing murine full-blown leukemia. Blood 2012, 119, 2873–2882. [CrossRef] [PubMed]
74. Rubin, C.M.; Larson, R.A.; Anastasi, J.; Winter, J.N.; Thangavelu, M.; Vardiman, J.W.; Rowley, J.D.;
Le Beau, M.M. t (3; 21)(q26; q22): A recurring chromosomal abnormality in therapy-related myelodysplastic
syndrome and acute myeloid leukemia. Blood 1990, 76, 2594–2598. [CrossRef] [PubMed]
75. Nucifora, G.; Begy, C.R.; Kobayashi, H.; Roulston, D.; Claxton, D.; Pedersen-Bjergaard, J.; Parganas, E.;
Ihle, J.N.; Rowley, J.D. Consistent intergenic splicing and production of multiple transcripts between AML1
at 21q22 and unrelated genes at 3q26 in (3; 21)(q26; q22) translocations. Proc. Natl. Acad. Sci. USA 1994, 91,
4004–4008. [CrossRef] [PubMed]
76. Nucifora, G.; Rowley, J.D. AML1 and the 8; 21 and 3; 21 translocations in acute and chronic myeloid leukemia.
Blood 1995, 86, 1–14. [CrossRef]
77. Lugthart, S.; Gröschel, S.; Beverloo, H.B.; Kayser, S.; Valk, P.J.M.; van Zelderen-Bhola, S.L.;
Jan Ossenkoppele, G.; Vellenga, E.; van den Berg-de Ruiter, E.; Schanz, U. Clinical, molecular, and prognostic
significance of WHO type inv (3)(q21q26. 2)/t (3; 3)(q21; q26. 2) and various other 3q abnormalities in acute
myeloid leukemia. J. Clin. Oncol. 2010, 28, 3890–3898. [CrossRef]
78. Nukina, A.; Kagoya, Y.; Watanabe-Okochi, N.; Arai, S.; Ueda, K.; Yoshimi, A.; Nannya, Y.; Kurokawa, M.
Single-cell gene expression analysis reveals clonal architecture of blast-phase chronic myeloid leukaemia.
Br. J. Haematol. 2014, 165, 414–416. [CrossRef]
Int. J. Mol. Sci. 2019, 20, 6141 18 of 23
79. Goyama, S.; Yamamoto, G.; Shimabe, M.; Sato, T.; Ichikawa, M.; Ogawa, S.; Chiba, S.; Kurokawa, M. Evi-1
is a critical regulator for hematopoietic stem cells and transformed leukemic cells. Cell Stem Cell 2008, 3,
207–220. [CrossRef]
80. Shen, L.; Zhu, J.; Chen, F.; Lin, W.; Cai, J.; Zhong, J.; Zhong, H. RUNX1-Evi-1 fusion gene inhibited
differentiation and apoptosis in myelopoiesis: An in vivo study. BMC Cancer 2015, 15, 970. [CrossRef]
81. Sill, H.; Goldman, J.M.; Cross, N.C. Homozygous deletions of the p16 tumor-suppressor gene are associated
with lymphoid transformation of chronic myeloid leukemia. Blood 1995, 85, 2013–2016. [CrossRef]
82. Hernández-Boluda, J.-C.; Cervantes, F.; Colomer, D.; Vela, M.-C.; Costa, D.; Paz, M.-F.; Esteller, M.;
Montserrat, E. Genomic p16 abnormalities in the progression of chronic myeloid leukemia into blast crisis:
A sequential study in 42 patients. Exp. Hematol. 2003, 31, 204–210. [CrossRef]
83. Williams, R.T.; Sherr, C.J. The INK4-ARF (CDKN2A/B) Locus in Hematopoiesis and BCR-ABL–induced
Leukemias. In Cold Spring Harbor Symposia on Quantitative Biology; Cold Spring Harbor Laboratory Press:
Woodbury, NY, USA, 2008; Volume 73, pp. 461–467.
84. Nacheva, E.P.; Brazma, D.; Virgili, A.; Howard-Reeves, J.; Chanalaris, A.; Gancheva, K.; Apostolova, M.;
Valgañon, M.; Mazzullo, H.; Grace, C. Deletions of immunoglobulin heavy chain and T cell receptor
gene regions are uniquely associated with lymphoid blast transformation of chronic myeloid leukemia.
BMC Genomics 2010, 11, 41. [CrossRef] [PubMed]
85. Huh, J.; Jung, C.W.; Kim, J.W.; Kim, H.-J.; Kim, S.-H.; Shin, M.G.; Kim, Y.K.; Kim, H.J.; Suh, J.S.; Moon, J.H.
Genome-wide high density single-nucleotide polymorphism array-based karyotyping improves detection of
clonal aberrations including der (9) deletion, but does not predict treatment outcomes after imatinib therapy
in chronic myeloid leukemia. Ann. Hematol. 2011, 90, 1255–1264. [CrossRef] [PubMed]
86. Mullighan, C.G.; Miller, C.B.; Radtke, I.; Phillips, L.A.; Dalton, J.; Ma, J.; White, D.; Hughes, T.P.; Le Beau, M.M.;
Pui, C.-H. BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 2008, 453,
110. [CrossRef]
87. Georgopoulos, K.; Moore, D.D.; Derfler, B. Ikaros, an early lymphoid-specific transcription factor and a
putative mediator for T cell commitment. Science 1992, 258, 808–812. [CrossRef]
88. Molnár, Á.; Wu, P.; Largespada, D.A.; Vortkamp, A.; Scherer, S.; Copeland, N.G.; Jenkins, N.A.; Bruns, G.;
Georgopoulos, K. The Ikaros gene encodes a family of lymphocyte-restricted zinc finger DNA binding
proteins, highly conserved in human and mouse. J. Immunol. 1996, 156, 585–592.
89. Sun, L.; Goodman, P.A.; Wood, C.M.; Crotty, M.-L.; Sensel, M.; Sather, H.; Navara, C.; Nachman, J.;
Steinherz, P.G.; Gaynon, P.S. Expression of aberrantly spliced oncogenic ikaros isoforms in childhood acute
lymphoblastic leukemia. J. Clin. Oncol. 1999, 17, 3753–3766. [CrossRef]
90. Iacobucci, I.; Lonetti, A.; Messa, F.; Cilloni, D.; Arruga, F.; Ottaviani, E.; Paolini, S.; Papayannidis, C.;
Piccaluga, P.P.; Giannoulia, P. Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute
lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: Implications for a new mechanism
of resistance. Blood 2008, 112, 3847–3855. [CrossRef]
91. Wang, L.; Howarth, A.; Clark, R.E. Ikaros transcripts Ik6/10 and levels of full-length transcript are critical for
chronic myeloid leukaemia blast crisis transformation. Leukemia 2014, 28, 1745. [CrossRef]
92. Soverini, S.; Score, J.; Iacobucci, I.; Poerio, A.; Lonetti, A.; Gnani, A.; Colarossi, S.; Ferrari, A.; Castagnetti, F.;
Rosti, G. IDH2 somatic mutations in chronic myeloid leukemia patients in blast crisis. Leukemia 2011, 25, 178.
[CrossRef]
93. Grossmann, V.; Kohlmann, A.; Zenger, M.; Schindela, S.; Eder, C.; Weissmann, S.; Schnittger, S.; Kern, W.;
Müller, M.C.; Hochhaus, A. A deep-sequencing study of chronic myeloid leukemia patients in blast crisis
(BC-CML) detects mutations in 76.9% of cases. Leukemia 2011, 25, 557. [CrossRef] [PubMed]
94. Makishima, H.; Jankowska, A.M.; McDevitt, M.A.; O’Keefe, C.; Dujardin, S.; Cazzolli, H.; Przychodzen, B.;
Prince, C.; Nicoll, J.; Siddaiah, H. CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional
chromosomal aberrations constitute molecular events in chronic myelogenous leukemia. Blood 2011, 117,
e198–e206. [CrossRef] [PubMed]
95. Magistroni, V.; Mauri, M.; D’Aliberti, D.; Mezzatesta, C.; Crespiatico, I.; Nava, M.; Fontana, D.; Sharma, N.;
Parker, W.; Schreiber, A. De novo UBE2A mutations are recurrently acquired during chronic myeloid
leukemia progression and interfere with myeloid differentiation pathways. Haematologica 2019, 2017, 179937.
[CrossRef] [PubMed]
Int. J. Mol. Sci. 2019, 20, 6141 19 of 23
96. Branford, S.; Wang, P.; Yeung, D.T.; Thomson, D.; Purins, A.; Wadham, C.; Shahrin, N.H.; Marum, J.E.;
Nataren, N.; Parker, W.T. Integrative genomic analysis reveals cancer-associated mutations at diagnosis of
CML in patients with high-risk disease. Blood 2018, 132, 948–961. [CrossRef]
97. Janssens, V.; Goris, J. Protein phosphatase 2A: A highly regulated family of serine/threonine phosphatases
implicated in cell growth and signalling. Biochem. J. 2001, 353, 417–439. [CrossRef]
98. Neviani, P.; Santhanam, R.; Trotta, R.; Notari, M.; Blaser, B.W.; Liu, S.; Mao, H.; Chang, J.S.; Galietta, A.;
Uttam, A. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory
activity of the BCR/ABL-regulated SET protein. Cancer Cell 2005, 8, 355–368. [CrossRef]
99. Perrotti, D.; Cesi, V.; Trotta, R.; Guerzoni, C.; Santilli, G.; Campbell, K.; Iervolino, A.; Condorelli, F.;
Gambacorti-Passerini, C.; Caligiuri, M.A. BCR-ABL suppresses C/EBPα expression through inhibitory action
of hnRNP E2. Nat. Genet. 2002, 30, 48. [CrossRef]
100. Radomska, H.S.; Huettner, C.S.; Zhang, P.U.; Cheng, T.A.O.; Scadden, D.T.; Tenen, D.G. CCAAT/enhancer
binding protein α is a regulatory switch sufficient for induction of granulocytic development from bipotential
myeloid progenitors. Mol. Cell. Biol. 1998, 18, 4301–4314. [CrossRef]
101. Notari, M.; Neviani, P.; Santhanam, R.; Blaser, B.W.; Chang, J.-S.; Galietta, A.; Willis, A.E.; Roy, D.C.;
Caligiuri, M.A.; Marcucci, G. A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating
MYC mRNA translation. Blood 2006, 107, 2507–2516. [CrossRef]
102. Chang, J.S.; Santhanam, R.; Trotta, R.; Neviani, P.; Eiring, A.M.; Briercheck, E.; Ronchetti, M.;
Roy, D.C.; Calabretta, B.; Caligiuri, M.A. High levels of the BCR/ABL oncoprotein are required for the
MAPK-hnRNP-E2–dependent suppression of C/EBPα-driven myeloid differentiation. Blood 2007, 110,
994–1003. [CrossRef]
103. Eiring, A.M.; Harb, J.G.; Neviani, P.; Garton, C.; Oaks, J.J.; Spizzo, R.; Liu, S.; Schwind, S.; Santhanam, R.;
Hickey, C.J. miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in
leukemic blasts. Cell 2010, 140, 652–665. [CrossRef] [PubMed]
104. Nelkin, B.D.; Przepiorka, D.; Burke, P.J.; Thomas, E.D.; Baylin, S.B. Abnormal methylation of the calcitonin
gene marks progression of chronic myelogenous leukemia. Blood 1991, 77, 2431–2434. [CrossRef] [PubMed]
105. Issa, J.-P.J.; Zehnbauer, B.A.; Civin, C.I.; Collector, M.I.; Sharkis, S.J.; Davidson, N.E.; Kaufmann, S.H.;
Baylin, S.B. The estrogen receptor CpG island is methylated in most hematopoietic neoplasms. Cancer Res.
1996, 56, 973–977. [PubMed]
106. Issa, J.-P.J.; Zehnbauer, B.A.; Kaufmann, S.H.; Biel, M.A.; Baylin, S.B. HIC1 hypermethylation is a late event
in hematopoietic neoplasms. Cancer Res. 1997, 57, 1678–1681.
107. Nguyen, T.T.; Mohrbacher, A.F.; Tsai, Y.C.; Groffen, J.; Heisterkamp, N.; Nichols, P.W.; Mimi, C.Y.; Lübbert, M.;
Jones, P.A. Quantitative measure of c-abl andp15 methylation in chronic myelogenous leukemia: Biological
implications. Blood 2000, 95, 2990–2992. [CrossRef]
108. Roman-Gomez, J.; Castillejo, J.A.; Jimenez, A.; Cervantes, F.; Boque, C.; Hermosin, L.; Leon, A.; Grañena, A.;
Colomer, D.; Heiniger, A. Cadherin-13, a mediator of calcium-dependent cell-cell adhesion, is silenced by
methylation in chronic myeloid leukemia and correlates with pretreatment risk profile and cytogenetic
response to interferon alfa. J. Clin. Oncol. 2003, 21, 1472–1479. [CrossRef]
109. Strathdee, G.; Holyoake, T.L.; Sim, A.; Parker, A.; Oscier, D.G.; Melo, J.V.; Meyer, S.; Eden, T.; Dickinson, A.M.;
Mountford, J.C. Inactivation of HOXA genes by hypermethylation in myeloid and lymphoid malignancy is
frequent and associated with poor prognosis. Clin. Cancer Res. 2007, 13, 5048–5055. [CrossRef]
110. Jelinek, J.; Gharibyan, V.; Estecio, M.R.H.; Kondo, K.; He, R.; Chung, W.; Lu, Y.; Zhang, N.; Liang, S.;
Kantarjian, H.M. Aberrant DNA methylation is associated with disease progression, resistance to imatinib
and shortened survival in chronic myelogenous leukemia. PLoS ONE 2011, 6, e22110. [CrossRef]
111. Heller, G.; Topakian, T.; Altenberger, C.; Cerny-Reiterer, S.; Herndlhofer, S.; Ziegler, B.; Datlinger, P.;
Byrgazov, K.; Bock, C.; Mannhalter, C. Next-generation sequencing identifies major DNA methylation
changes during progression of Ph+ chronic myeloid leukemia. Leukemia 2016, 30, 1861. [CrossRef]
112. Trotta, R.; Vignudelli, T.; Candini, O.; Intine, R.V.; Pecorari, L.; Guerzoni, C.; Santilli, G.; Byrom, M.W.;
Goldoni, S.; Ford, L.P. BCR/ABL activates mdm2 mRNA translation via the La antigen. Cancer Cell 2003, 3,
145–160. [CrossRef]
113. Perrotti, D.; Bonatti, S.; Trotta, R.; Martinez, R.; Skorski, T.; Salomoni, P.; Grassilli, E.; Iozzo, R.V.; Cooper, D.R.;
Calabretta, B. TLS/FUS, a pro-oncogene involved in multiple chromosomal translocations, is a novel regulator
of BCR/ABL-mediated leukemogenesis. EMBO J. 1998, 17, 4442–4455. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2019, 20, 6141 20 of 23
114. Guerzoni, C.; Bardini, M.; Mariani, S.A.; Ferrari-Amorotti, G.; Neviani, P.; Panno, M.L.; Zhang, Y.; Martinez, R.;
Perrotti, D.; Calabretta, B. Inducible activation of CEBPB, a gene negatively regulated by BCR/ABL, inhibits
proliferation and promotes differentiation of BCR/ABL-expressing cells. Blood 2006, 107, 4080–4089. [CrossRef]
[PubMed]
115. Eiring, A.M.; Neviani, P.; Santhanam, R.; Oaks, J.J.; Chang, J.S.; Notari, M.; Willis, W.; Gambacorti-Passerini, C.;
Volinia, S.; Marcucci, G. Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein
by ribonomics: Requirement of E2F3 for BCR/ABL leukemogenesis. Blood 2008, 111, 816–828. [CrossRef]
[PubMed]
116. Ly, C.; Arechiga, A.F.; Melo, J.V.; Walsh, C.M.; Ong, S.T. Bcr-Abl kinase modulates the translation regulators
ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of
rapamycin. Cancer Res. 2003, 63, 5716–5722.
117. Perrotti, D.; Turturro, F.; Neviani, P. BCR/ABL, mRNA translation and apoptosis. Cell Death Differ. 2005, 12,
534–540. [CrossRef]
118. Jiang, Q.; Crews, L.A.; Barrett, C.L.; Chun, H.-J.; Isquith, J.M.; Zipeto, M.A.; Goff, D.J.; Minden, M.;
Sadarangani, A.; Rusert, J.M. ADAR1 promotes malignant progenitor reprogramming in chronic myeloid
leukemia. Proc. Natl. Acad. Sci. USA 2013, 110, 1041–1046. [CrossRef]
119. Zipeto, M.A.; Court, A.C.; Sadarangani, A.; Santos, N.P.D.; Balaian, L.; Chun, H.-J.; Pineda, G.; Morris, S.R.;
Mason, C.N.; Geron, I. ADAR1 activation drives leukemia stem cell self-renewal by impairing Let-7 biogenesis.
Cell Stem Cell 2016, 19, 177–191. [CrossRef]
120. Crews, L.A.; Jiang, Q.; Zipeto, M.A.; Lazzari, E.; Ali, S.; Barrett, C.L.; Frazer, K.A.; Jamieson, C.H.M. An RNA
editing fingerprint of cancer stem cell reprogramming. J. Transl. Med. 2015, 13, 52. [CrossRef]
121. Garzon, R.; Calin, G.A.; Croce, C.M. MicroRNAs in cancer. Annu. Rev. Med. 2009, 60, 167–179. [CrossRef]
122. Garzon, R.; Fabbri, M.; Cimmino, A.; Calin, G.A.; Croce, C.M. MicroRNA expression and function in cancer.
Trends Mol. Med. 2006, 12, 580–587. [CrossRef]
123. Si, W.; Shen, J.; Zheng, H.; Fan, W. The role and mechanisms of action of microRNAs in cancer drug resistance.
Clin. Epigenetics 2019, 11, 25. [CrossRef]
124. Poláková, K.M.; Lopotová, T.; Klamová, H.; Burda, P.; Trneˇný, M.; Stopka, T.; Moravcová, J. Expression
patterns of microRNAs associated with CML phases and their disease related targets. Mol. Cancer 2011, 10,
41. [CrossRef]
125. Srutova, K.; Curik, N.; Burda, P.; Savvulidi, F.; Silvestri, G.; Trotta, R.; Klamova, H.; Pecherkova, P.;
Sovova, Z.; Koblihova, J. BCR-ABL1 mediated miR-150 downregulation through MYC contributed to
myeloid differentiation block and drug resistance in chronic myeloid leukemia. Haematologica 2018, 103,
2016–2025. [CrossRef] [PubMed]
126. Hattori, A.; Tsunoda, M.; Konuma, T.; Kobayashi, M.; Nagy, T.; Glushka, J.; Tayyari, F.; McSkimming, D.;
Kannan, N.; Tojo, A. Cancer progression by reprogrammed BCAA metabolism in myeloid leukaemia. Nature
2017, 545, 500. [CrossRef] [PubMed]
127. Bar-Peled, L.; Sabatini, D.M. Regulation of mTORC1 by amino acids. Trends Cell Biol. 2014, 24, 400–406.
[CrossRef] [PubMed]
128. Ito, T.; Kwon, H.Y.; Zimdahl, B.; Congdon, K.L.; Blum, J.; Lento, W.E.; Zhao, C.; Lagoo, A.; Gerrard, G.;
Foroni, L. Regulation of myeloid leukaemia by the cell-fate determinant Musashi. Nature 2010, 466, 765.
[CrossRef]
129. Kharas, M.G.; Lengner, C.J.; Al-Shahrour, F.; Bullinger, L.; Ball, B.; Zaidi, S.; Morgan, K.; Tam, W.; Paktinat, M.;
Okabe, R. Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia. Nat. Med.
2010, 16, 903. [CrossRef]
130. Hughes, T.; Deininger, M.; Hochhaus, A.; Branford, S.; Radich, J.; Kaeda, J.; Baccarani, M.; Cortes, J.;
Cross, N.C.P.; Druker, B.J. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors:
Review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and
kinase domain mutations and for expressing results. Blood 2006, 108, 28–37. [CrossRef]
131. Hughes, T.P.; Kaeda, J.; Branford, S.; Rudzki, Z.; Hochhaus, A.; Hensley, M.L.; Gathmann, I.; Bolton, A.E.; Van
Hoomissen, I.C.; Goldman, J.M. Frequency of major molecular responses to imatinib or interferon alfa plus
cytarabine in newly diagnosed chronic myeloid leukemia. N. Engl. J. Med. 2003, 349, 1423–1432. [CrossRef]
Int. J. Mol. Sci. 2019, 20, 6141 21 of 23
132. Patel, A.B.; O’Hare, T.; Deininger, M.W. Mechanisms of resistance to ABL kinase inhibition in chronic myeloid
leukemia and the development of next generation ABL kinase inhibitors. Hematol. Clin. 2017, 31, 589–612.
[CrossRef]
133. Soverini, S.; Mancini, M.; Bavaro, L.; Cavo, M.; Martinelli, G. Chronic myeloid leukemia: The paradigm of
targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy.
Mol. Cancer 2018, 17, 49. [CrossRef] [PubMed]
134. Sundaram, D.N.M.; Jiang, X.; Brandwein, J.M.; Valencia-Serna, J.; Remant, K.C.; Uludag˘, H. Current outlook
on drug resistance in chronic myeloid leukemia (CML) and potential therapeutic options. Drug Discov. Today
2019.
135. Burchert, A.; Wang, Y.; Cai, D.; Von Bubnoff, N.; Paschka, P.; Müller-Brüsselbach, S.; Ottmann, O.G.; Duyster, J.;
Hochhaus, A.; Neubauer, A. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance
development. Leukemia 2005, 19, 1774. [CrossRef] [PubMed]
136. Wu, J.; Meng, F.; Lu, H.; Kong, L.; Bornmann, W.; Peng, Z.; Talpaz, M.; Donato, N.J. Lyn regulates BCR-ABL
and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous
leukemia cells. Blood 2008, 111, 3821–3829. [CrossRef]
137. Bellodi, C.; Lidonnici, M.R.; Hamilton, A.; Helgason, G.V.; Soliera, A.R.; Ronchetti, M.; Galavotti, S.;
Young, K.W.; Selmi, T.; Yacobi, R. Targeting autophagy potentiates tyrosine kinase inhibitor–induced cell
death in Philadelphia chromosome–positive cells, including primary CML stem cells. J. Clin. Invest. 2009,
119, 1109–1123. [CrossRef]
138. Esposito, N.; Colavita, I.; Quintarelli, C.; Sica, A.R.; Peluso, A.L.; Luciano, L.; Picardi, M.; Del Vecchio, L.;
Buonomo, T.; Hughes, T.P. SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia
chromosome–positive cells derived from patients with chronic myeloid leukemia. Blood 2011, 118, 3634–3644.
[CrossRef]
139. Wang, Z.; Yuan, H.; Roth, M.; Stark, J.M.; Bhatia, R.; Chen, W. SIRT1 deacetylase promotes acquisition of
genetic mutations for drug resistance in CML cells. Oncogene 2013, 32, 589. [CrossRef]
140. Ma, L.; Shan, Y.; Bai, R.; Xue, L.; Eide, C.A.; Ou, J.; Zhu, L.J.; Hutchinson, L.; Cerny, J.; Khoury, H.J.
A therapeutically targetable mechanism of BCR-ABL–independent imatinib resistance in chronic myeloid
leukemia. Sci. Transl. Med. 2014, 6, 252ra121. [CrossRef]
141. Eiring, A.M.; Page, B.D.G.; Kraft, I.L.; Mason, C.C.; Vellore, N.A.; Resetca, D.; Zabriskie, M.S.; Zhang, T.Y.;
Khorashad, J.S.; Engar, A.J. Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in
therapy-resistant chronic myeloid leukemia. Leukemia 2015, 29, 586. [CrossRef]
142. Khorashad, J.S.; Eiring, A.M.; Mason, C.C.; Gantz, K.C.; Bowler, A.D.; Redwine, H.M.; Yu, F.; Kraft, I.L.;
Pomicter, A.D.; Reynolds, K.R. shRNA library screening identifies nucleocytoplasmic transport as a mediator
of BCR-ABL1 kinase-independent resistance. Blood 2015, 125, 1772–1781. [CrossRef]
143. Walker, C.J.; Joshua, J.O.; Ramasamy, S.; Paolo, N.; J, G.H.; Gregory, F.; Justin, J.E.; Yosef, L.; Ann-Kathrin, E.;
Nash, Y.G. Preclinical and Clinical Efficacy of XPO1/CRM1 Inhibition by the Karyopherin Inhibitor KPT-330
in Ph+ Leukemias. Blood 2013, 122, 3034–3044. [CrossRef] [PubMed]
144. Chakraborty, S.N.; Leng, X.; Perazzona, B.; Sun, X.; Lin, Y.-H.; Arlinghaus, R.B. Combination of jak2 and hsp90
inhibitors: An effective therapeutic option in drug-resistant chronic myelogenous leukemia. Genes Cancer
2016, 7, 201. [PubMed]
145. Wagle, M.; Eiring, A.M.; Wongchenko, M.; Lu, S.; Guan, Y.; Wang, Y.; Lackner, M.; Amler, L.; Hampton, G.;
Deininger, M.W. A role for FOXO1 in BCR–ABL1-independent tyrosine kinase inhibitor resistance in chronic
myeloid leukemia. Leukemia 2016, 30, 1493. [CrossRef] [PubMed]
146. Scott, M.T.; Korfi, K.; Saffrey, P.; Hopcroft, L.E.M.; Kinstrie, R.; Pellicano, F.; Guenther, C.; Gallipoli, P.;
Cruz, M.; Dunn, K. Epigenetic reprogramming sensitizes CML stem cells to combined EZH2 and tyrosine
kinase inhibition. Cancer Discov. 2016, 6, 1248–1257. [CrossRef] [PubMed]
147. Zhou, H.; Mak, P.Y.; Mu, H.; Mak, D.H.; Zeng, Z.; Cortes, J.; Liu, Q.; Andreeff, M.; Carter, B.Z. Combined
inhibition of β-catenin and Bcr–Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis
chronic myeloid leukemia blasts and progenitors in vitro and in vivo. Leukemia 2017, 31, 2065. [CrossRef]
148. Eiring, A.M.; Jonathan, A.; Clinton, C.M.; Ethan, D.; Thomas, H.; Michael, W.D. Loss of G0S2 in
Kinase-Independent TKI Resistance and Blastic Transformation of CML. Am Soc. Hematol. 2017, 4173.
149. Zhu, Y.; Lu, L.; Qiao, C.; Shan, Y.; Li, H.; Qian, S.; Hong, M.; Zhao, H.; Li, J.; Yang, Z. Targeting PFKFB3
sensitizes chronic myelogenous leukemia cells to tyrosine kinase inhibitor. Oncogene 2018, 37, 2837. [CrossRef]
Int. J. Mol. Sci. 2019, 20, 6141 22 of 23
150. Bhatia, R.; Holtz, M.; Niu, N.; Gray, R.; Snyder, D.S.; Sawyers, C.L.; Arber, D.A.; Slovak, M.L.; Forman, S.J.
Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete
cytogenetic remission following imatinib mesylate treatment. Blood 2003, 101, 4701–4707. [CrossRef]
151. Chu, S.; McDonald, T.; Lin, A.; Chakraborty, S.; Huang, Q.; Snyder, D.S.; Bhatia, R. Persistence of leukemia
stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment. Blood
2011, 118, 5565–5572. [CrossRef]
152. Chomel, J.-C.; Bonnet, M.-L.; Sorel, N.; Bertrand, A.; Meunier, M.-C.; Fichelson, S.; Melkus, M.;
Bennaceur-Griscelli, A.; Guilhot, F.; Turhan, A.G. Leukemic stem cell persistence in chronic myeloid
leukemia patients with sustained undetectable molecular residual disease. Blood 2011, 118, 3657–3660.
[CrossRef]
153. Chomel, J.C.; Bonnet, M.L.; Sorel, N.; Sloma, I.; Bennaceur-Griscelli, A.; Rea, D.; Legros, L.; Marfaing-Koka, A.;
Bourhis, J.-H.; Ame, S. Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular
response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation. Oncotarget 2016,
7, 35293. [CrossRef] [PubMed]
154. Bocchia, M.; Sicuranza, A.; Abruzzese, E.; Iurlo, A.; Sirianni, S.; Gozzini, A.; Galimberti, S.; Aprile, L.;
Martino, B.; Pregno, P. Residual peripheral blood CD26+ leukemic stem cells in chronic myeloid leukemia
patients during TKI therapy and during treatment-free remission. Front. Oncol. 2018, 30, 194–201. [CrossRef]
[PubMed]
155. Graham, S.M.; Jørgensen, H.G.; Allan, E.; Pearson, C.; Alcorn, M.J.; Richmond, L.; Holyoake, T.L. Primitive,
quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to
STI571 in vitro. Blood 2002, 99, 319–325. [CrossRef] [PubMed]
156. Jørgensen, H.G.; Allan, E.K.; Jordanides, N.E.; Mountford, J.C.; Holyoake, T.L. Nilotinib exerts equipotent
antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. Blood 2007, 109,
4016–4019. [CrossRef]
157. Corbin, A.S.; Agarwal, A.; Loriaux, M.; Cortes, J.; Deininger, M.W.; Druker, B.J. Human chronic myeloid
leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J. Clin. Invest. 2011,
121, 396–409. [CrossRef]
158. Hamilton, A.; Helgason, G.V.; Schemionek, M.; Zhang, B.; Myssina, S.; Allan, E.K.; Nicolini, F.E.;
Müller-Tidow, C.; Bhatia, R.; Brunton, V.G. Chronic myeloid leukemia stem cells are not dependent
on Bcr-Abl kinase activity for their survival. Blood 2012, 119, 1501–1510. [CrossRef]
159. Neviani, P.; Harb, J.G.; Oaks, J.J.; Santhanam, R.; Walker, C.J.; Ellis, J.J.; Ferenchak, G.; Dorrance, A.M.;
Paisie, C.A.; Eiring, A.M. PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic
stem cells. J. Clin. Invest. 2013, 123, 4144–4157. [CrossRef]
160. Holyoake, T.L.; Vetrie, D. The chronic myeloid leukemia stem cell: Stemming the tide of persistence. Blood
2017, 129, 1595–1606. [CrossRef]
161. Modi, H.; McDonald, T.; Chu, S.; Yee, J.-K.; Forman, S.J.; Bhatia, R. Role of BCR/ABL gene-expression levels
in determining the phenotype and imatinib sensitivity of transformed human hematopoietic cells. Blood
2007, 109, 5411–5421. [CrossRef]
162. Kumari, A.; Brendel, C.; Hochhaus, A.; Neubauer, A.; Burchert, A. Low BCR-ABL expression levels in
hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinib. Blood 2012,
119, 530–539. [CrossRef]
163. Naka, K.; Hoshii, T.; Muraguchi, T.; Tadokoro, Y.; Ooshio, T.; Kondo, Y.; Nakao, S.; Motoyama, N.; Hirao, A.
TGF-β–FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature 2010,
463, 676. [CrossRef] [PubMed]
164. Pellicano, F.; Scott, M.T.; Helgason, G.V.; Hopcroft, L.E.M.; Allan, E.K.; Aspinall-O’Dea, M.; Copland, M.;
Pierce, A.; Huntly, B.J.P.; Whetton, A.D. The antiproliferative activity of kinase inhibitors in chronic myeloid
leukemia cells is mediated by FOXO transcription factors. Stem Cells 2014, 32, 2324–2337. [CrossRef]
[PubMed]
165. Dierks, C.; Beigi, R.; Guo, G.-R.; Zirlik, K.; Stegert, M.R.; Manley, P.; Trussell, C.; Schmitt-Graeff, A.;
Landwerlin, K.; Veelken, H. Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog
pathway activation. Cancer Cell 2008, 14, 238–249. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2019, 20, 6141 23 of 23
166. Zhao, C.; Chen, A.; Jamieson, C.H.; Fereshteh, M.; Abrahamsson, A.; Blum, J.; Kwon, H.Y.; Kim, J.; Chute, J.P.;
Rizzieri, D. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia.
Nature 2009, 458, 776. [CrossRef]
167. Reya, T.; Duncan, A.W.; Ailles, L.; Domen, J.; Scherer, D.C.; Willert, K.; Hintz, L.; Nusse, R.; Weissman, I.L.
A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature 2003, 423, 409. [CrossRef]
168. Zhao, C.; Blum, J.; Chen, A.; Kwon, H.Y.; Jung, S.H.; Cook, J.M.; Lagoo, A.; Reya, T. Loss of β-catenin impairs
the renewal of normal and CML stem cells in vivo. Cancer Cell 2007, 12, 528–541. [CrossRef]
169. Krause, D.S.; Lazarides, K.; von Andrian, U.H.; Van Etten, R.A. Requirement for CD44 in homing and
engraftment of BCR-ABL–expressing leukemic stem cells. Nat. Med. 2006, 12, 1175. [CrossRef]
170. Krause, D.S.; Lazarides, K.; Lewis, J.B.; von Andrian, U.H.; Van Etten, R.A. Selectins and their ligands are
required for homing and engraftment of BCR-ABL1+ leukemic stem cells in the bone marrow niche. Blood
2014, 123, 1361–1371. [CrossRef]
171. Yamamoto-Sugitani, M.; Kuroda, J.; Ashihara, E.; Nagoshi, H.; Kobayashi, T.; Matsumoto, Y.; Sasaki, N.;
Shimura, Y.; Kiyota, M.; Nakayama, R. Galectin-3 (Gal-3) induced by leukemia microenvironment promotes
drug resistance and bone marrow lodgment in chronic myelogenous leukemia. Proc. Natl. Acad. Sci. USA
2011, 108, 17468–17473. [CrossRef]
172. Zhang, B.; Ho, Y.W.; Huang, Q.; Maeda, T.; Lin, A.; Lee, S.; Hair, A.; Holyoake, T.L.; Huettner, C.; Bhatia, R.
Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia.
Cancer Cell 2012, 21, 577–592. [CrossRef]
173. Mumprecht, S.; Schürch, C.; Schwaller, J.; Solenthaler, M.; Ochsenbein, A.F. Programmed death 1 signaling
on chronic myeloid leukemia–specific T cells results in T-cell exhaustion and disease progression. Blood 2009,
114, 1528–1536. [CrossRef] [PubMed]
174. Riether, C.; Schürch, C.M.; Ochsenbein, A.F. Regulation of hematopoietic and leukemic stem cells by the
immune system. Cell Death Differ. 2015, 22, 187. [CrossRef] [PubMed]
175. Tarafdar, A.; Hopcroft, L.E.M.; Gallipoli, P.; Pellicano, F.; Cassels, J.; Hair, A.; Korfi, K.; Jørgensen, H.G.;
Vetrie, D.; Holyoake, T.L. CML cells actively evade host immune surveillance through cytokine-mediated
downregulation of MHC-II expression. Blood 2017, 129, 199–208. [CrossRef] [PubMed]
176. Marum, J.E.; Wang, P.P.S.; Stangl, D.; Yeung, D.T.; Mueller, M.C.; Dietz, C.T.; Walker, I.; Nataren, N.;
Donaldson, Z.; Parker, W.T. Novel fusion genes at CML diagnosis reveal a complex pattern of genomic
rearrangements and sequence inversions associated with the Philadelphia chromosome in patients with
early blast crisis. Blood 2016, 128, 1219. [CrossRef]
177. Marum, J.E.; Yeung, D.T.; Purins, L.; Reynolds, J.; Parker, W.T.; Stangl, D.; Wang, P.P.S.; Price, D.J.; Tuke, J.;
Schreiber, A.W. ASXL1 and BIM germ line variants predict response and identify CML patients with the
greatest risk of imatinib failure. Blood Adv. 2017, 1, 1369–1381. [CrossRef] [PubMed]
178. Lucas, C.M.; Harris, R.J.; Giannoudis, A.; Copland, M.; Slupsky, J.R.; Clark, R.E. Cancerous inhibitor of PP2A
(CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression. Blood 2011,
117, 6660–6668. [CrossRef] [PubMed]
179. Rousselot, P.; Prost, S.; Guilhot, J.; Roy, L.; Etienne, G.; Legros, L.; Charbonnier, A.; Coiteux, V.;
Cony-Makhoul, P.; Huguet, F. Pioglitazone together with imatinib in chronic myeloid leukemia: A proof of
concept study. Cancer 2017, 123, 1791–1799. [CrossRef]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
